Document:

EX-10.22

 Exhibit 10.22 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

ASSET PURCHASE AGREEMENT 

THIS ASSET PURCHASE AGREEMENT is made as of this 6th day of November, 2009, by and among INTROGEN THERAPEUTICS, INC., a Delaware
corporation (“Introgen Therapeutics”) and INTROGEN TECHNICAL SERVICES, INC., a Delaware corporation (“Introgen Services”), as debtors and debtors-in-possession (each a “Seller” and together
“Sellers”), and POPE INVESTMENTS II LLC, a Delaware limited liability company (“Buyer”). 

WITNESSETH 
 WHEREAS,
Sellers are currently debtors and debtors-in-possession in a case under the Bankruptcy Code titled, In re Introgen Therapeutics, Inc. and Introgen Technical Services, Inc., Case No. 08-12442, in the Bankruptcy Court (the
“Bankruptcy Case”); 
 WHEREAS, Sellers intend to convey to Buyer Sellers’ assets, contracts and rights necessary or
useful for developing, obtaining regulatory approvals in the United States and abroad for, manufacturing, commercializing and marketing the Assets (defined below). 

WHEREAS, Buyer desires to acquire the assets, contracts and rights necessary to further develop, obtain regulatory approvals in the United
States and abroad for, manufacture, commercialize and market the Assets (defined below); 
 WHEREAS, Sellers and Buyer desire to set forth
their agreement with respect to the transfer of certain assets to, and the assumption of specified liabilities by, Buyer in exchange for the consideration specified herein; 

NOW THEREFORE, in consideration of the mutual promises contained herein, and intending to be legally bound, Sellers and Buyer do hereby agree
as follows: 
 ARTICLE I 

TRANSFER OF ASSETS 
 1.1
Assets. 
 (a) Transferred Assets. Except as to any Excluded Assets, Sellers hereby agree to contribute, convey, grant,
assign and transfer, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Order Approving Debtors’ Motion to Sell Property Under Section 363(b) of the Bankruptcy Code, dated October 8, 2009, as the same
may be amended pursuant to Section 3.2 below (the “Sale Order”) to Buyer at the Closing, and Buyer hereby agrees to accept from Sellers at the Closing, the following assets, properties, rights and privileges owned, used
or held for use by Sellers as described below (the “Assets”): 
 (1) All of Sellers’ interest, right and title to the
patents and related intellectual property rights listed on Schedule 1.1(0(1) (the “Transferred Intellectual Property Rights”); 

 (2) The contracts listed on Schedule 1.1(a)(2) (the “Assumed
Contracts”); 
 (3) All vials of Advexin owned by Sellers as of the date of this Agreement and not previously sold including,
specifically, without limitation, those vials and other items of personal property listed on Schedule 1.1(a)(3) (the “Transferred Personal Property”); 

(4) All of Sellers’ equity interest in VirRx; Inc., a Delaware corporation, which is understood to be a 49% interest, and all of
Seller’s rights under any shareholder agreements, investment contracts or other agreements effecting or related to the equity interest in VirRx; Inc., but subject to any restrictions on transfer set forth in any such agreements, provided,
however, that Sellers will use commercially reasonable efforts to resolve any transfer restrictions and effect the transfer; and 
 (5)
All other assets, materials, properties, rights and privileges owned, controlled, used or held for use by Sellers in connection with the Transferred Intellectual Property Rights, the Assumed Contracts and the Transferred Personal Property, or
relating to the programs listed on Schedule 1.1(a)(5) attached hereto (“Programs”), other than the Excluded Assets, including but not limited to trademarks, regulatory filings and correspondence, clinical, preclinical
and other data, documentation, biological materials, tangible research materials, and rights arising under or relating to any and all protective covenant, noncompetition, nonsolicitation, confidentiality or similar agreements relative to the Assets
or Programs, and rights or claims arising thereunder. 
 To the extent that any of the Assets for whatever reason are not or cannot be
conveyed, assigned or transferred by Sellers to Buyer at Closing (other than Additional Contracts which are dealt with separately herein), Sellers hereby agree to take such actions requested by Buyer as may be reasonably necessary (including but not
limited to granting Buyer a sublicense with respect to such Assets and maintaining any license required to be maintained for such sublicense to survive) to give Buyer the benefits of such Assets for no additional consideration beyond the Purchase
Price. 
 (b) Excluded Assets. “Excluded Assets” shall include the following: 

(1) The consideration delivered to Sellers pursuant to this Agreement; 

(2) All assets previously transferred to Crucell Holland, B.V. (“Crucell”) under, and all future royalties, payments and
contingent proceeds due to Sellers pursuant to, the Patent Purchase Agreement between Introgen Therapeutics and Crucell Holland B.V., dated May 15, 2009; 

(3) All assets previously transferred to Vivante GMP Solutions, Inc. (“Vivante”) under, and all future royalties, payments
and contingent proceeds due to Sellers pursuant to, the Asset Purchase Agreement between Sellers and Western General Holdings / Vivante GMP Solutions, Inc., dated June 1, 2009 (the “Vivante Agreement”); 

(4) 350 vials of Advexin previously sold to Moffitt Cancer Center; 

(5) All of Sellers’ right title and interest in and to any and all intellectual property that relates solely to or is useful solely for
Introgen Therapeutics’s FUS1 program; provided, however, that Sellers acknowledge and agree that none of the items listed in Schedules 1.1(a)(1), 1.1(a)(2) or 1.1 (a)(3) will be considered FUS1 intellectual property for purposes of this
provision; 
 (6) All causes of action arising under 11 U.S.C. § 542, 543, 544, 545, 546, 547, 548, 549 and 555; 

  
 2 

 (7) All causes of action instituted by Sellers before the Closing Date (together with any
underlying employment agreement, personnel agreement or similar agreement to the extent related to any such causes of action filed prior to the Closing Date), and all other causes of action brought by the Liquidating Trustee of the Sellers,
including, but not limited to, patent infringement claims that arose prior to the Closing Date, but excluding such patent infringement claims relating to the Assets, that have not been brought by the Sellers or Liquidating Trustee of the Sellers
prior to the Closing Date; 
 (8) All stock and other equity interests or financial or ownership interests in Sellers’ subsidiaries
and any other entities except as such may be transferred to Buyer in accordance with the provisions contained in Section 3.2(f) hereof; and 

(9) One Seagate BlackArmor® NAS 440 4TB external hard drive, Product SKU: ST340005SHA10G-RK; provided, however, that any data
relating to the Assets and stored on such hard drive, to which the Buyer has access pursuant to Section 6.1, shall not be excluded hereunder; and 

(10) All cash, cash equivalents, trade accounts receivable, and other receivables of Sellers; provided that any receivables derived from the
Assets and arising after Closing shall belong to Buyer and will not be an Excluded Asset 
 (c) Contract Designation Rights. 

(1) A Seller is a party to that certain Restated P53 and K-Ras Agreement by and among Aventis Pharmaceuticals Products Inc., Aventis Pharma
S.A., and Introgen Therapeutics, Inc. dated June 30, 2001, as supplemented or amended (the “Aventis Agreement”). Each Seller may be a party to other agreements or contracts (in addition to the Assumed Contracts) that support or
are valuable to the development or marketability of the Assets, but such additional contracts are under review. From the date hereof until 5:00 p.m. central time on November 30, 2009 (the “Contract Designation Period”), Buyer
shall have the option to make designations as to the transfer, assumption and assignment of any contracts or agreements (other than the Assumed Contracts) that were entered into prior to the filing of the bankruptcy case and to which either Seller
is a party that, as of the date of this Agreement, have not been rejected, assumed or assigned by Sellers (together with the Aventis Agreement, the “Additional Contracts”) by delivering to Sellers a notice (a “Transfer
Notice”) of Buyer’s election to request Sellers to seek approval from the Bankruptcy Court to transfer, assume and assign one or more of such Additional Contracts to Buyer. Upon receipt of a Transfer Notice for an Additional Contract,
Sellers shall promptly file and serve an appropriate motion reasonably acceptable to Buyer and Sellers seeking the Bankruptcy Court’s approval of the transfer, assumption and assignment of such Additional Contract to Buyer. Contracts to which
any of Sellers’ wholly-owned subsidiaries are a party and which, if any Seller had been party to them would have been an Additional Contract, shall be addressed under the procedures outlined in Section 3.2(f). 

(2) By written notice (a “Withdrawal of Transfer Notice”) to Sellers at least two business days prior to the hearing on the
Sellers’ motion to transfer, assume and assign any Additional Contract that was the subject of a prior Transfer Notice, Buyer may withdraw its Transfer Notice with respect to one or more Additional Contracts and the Sellers shall withdraw its
motion with respect to such designated Additional Contracts only. 
 (3) Sellers represent that as of the date of execution of this
Agreement, they have not rejected the Aventis Agreement and covenant and agree not to take any action specifically intended to reject the Aventis Agreement or any Additional Contract prior to the Closing Date. Buyer acknowledges that any Additional
Contracts that are not on Schedule 1.1(a)(2) and that have not been added to the list of Assumed Contracts filed with the bankruptcy court will be deemed rejected upon the effective date of Sellers’

  
 3 

 
Plan of Reorganization and Sellers’ agree that prior to the earlier of (i) the Closing Date, (ii) the termination of this Agreement, or (iii) 150 days after the confirmation
of Sellers’ Plan of Reorganization, Sellers shall not have the plan of reorganization deemed effective, although Sellers will continue to vigorously pursue confirmation of their Plan of Reorganization, and nothing in this
Section 1.1 will prevent Sellers from doing so. 
 1.2 Purchase Price; Contingent Royalty Payments. In
addition to assuming the Assumed Liabilities, Buyer agrees to pay to Sellers, in the aggregate, the following consideration for the Assets: 

(a) At Closing, cash, wired funds, or other immediately available funds in the amount of One Million Dollars ($1,000,000.00), as adjusted
pursuant to Section 5.3 (the “Purchase Price”); 
 (b) Subject to Section 1.2(c) below, Buyer
agrees to pay to Sellers, as additional consideration for the Assets, upon such date a Net Sales objective identified in this section is achieved in full, the payment amount set forth for such objective (each such payment, if any, a
“Contingent Royalty Payment”). 
 (1) At such time as Net Sales first exceed $[***] dollars in the aggregate, a Contingent
Royalty Payment of [***]; 
 (2) At such time as Net Sales first exceed $[***] dollars in the aggregate, a Contingent Royalty Payment of
[***]; and 
 (3) At such time as Net Sales first exceed $[***] dollars in the aggregate, a final Contingent Royalty Payment of [***]. 

(c) Sellers acknowledge and agree that Buyer is an investor and not the entity that will further develop the Assets; that Buyer intends to
transfer or contribute its rights and obligations under this Agreement to P53, Inc. (the “Buyer Transferee”) prior to the Closing Date pursuant to the provisions of Section 10.3; and that upon such transfer to the Buyer
Transferee, Buyer shall be released from its obligations under this Agreement and the Buyer Transferee will assume all obligations of Buyer under this Agreement including, without limitation, the obligation to pay any Contingent Royalty Payments and
effective immediately upon such transfer, all references herein to “Buyer” shall mean the “Buyer Transferee”. The obligation of the Buyer to make Contingent Royalty Payments when due shall be irrevocable and shall survive the
Closing. In no case will the Purchase Price and all Contingent Royalty Payments exceed $31,000,000 in the aggregate to the Sellers. Buyer will act in good faith in calculating Net Sales and will not attempt to circumvent the definition of Net Sales
in any manner including through transactions with Affiliates of Buyer. 
 (d) Sellers acknowledge and agree that on and after the Closing
Date Buyer will own the Assets free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order and is under no obligation to pursue any particular course of action with respect to the development, pursuit of regulatory
approvals for, manufacture, commercialization and marketing of the Assets. Sellers acknowledge and agree that on and after the Closing Date any business decisions made by Buyer with respect to any of the Assets shall be solely in Buyer’s
discretion, that Buyer may sell, transfer, assign or license some or all of the Assets to third parties under such terms and conditions as it shall determine in its sole and absolute discretion, 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 4 

 
subject to Section 10.3 below and to Buyer’s obligation not to attempt to circumvent the definition of Net Sales as provided above, and that neither the Buyer nor any subsequent
purchaser, assignee, transferee, licensee or similarly situated Person shall have any obligation whatsoever to Sellers or its successors or assigns hereunder to (i) protect any patents that are part of the Assets or (ii) attempt to
monetize the Assets. 
 1.3 “As Is” Condition. Except as set forth in Article VII, the Assets shall be
conveyed to and accepted by Buyer on the Closing Date in an “as is,” “where is” and “with all faults” condition, free of any warranties or representations whatsoever, whether oral or written, express or implied, patent
or latent and each Seller EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND EACH SELLER EXPRESSLY
DISCLAIMS LIABILITY FOR LOSS OF PROFIT OR FOR INDIRECT, CONSEQUENTIAL OR COMMERCIAL LOSSES AND ALL OTHER OBLIGATIONS AND LIABILITIES (EXCEPT AS EXPRESSLY RETAINED BY SUCH SELLER HEREUNDER). 

1.4 Further Assurances. Each Seller, for itself and its respective successors and assigns, hereby covenants and agrees that,
without further consideration, at any time and from time to time after the Closing Date, it shall execute and deliver to Buyer such further instruments of sale, conveyance, assignment and transfer, and take such other action, all upon the request of
Buyer, in order to (a) further document or evidence the contribution, conveyance, grant, assignment, transfer and delivery of all or any portion of the Assets to Buyer, (b) assure and confirm to any other person the ownership of the Assets
by Buyer and (c) permit Buyer to exercise any of the franchises, rights, licenses or privileges intended to be contributed, granted, conveyed, assigned, transferred and delivered by each Seller to Buyer pursuant to this Agreement. 

ARTICLE II 
 ASSUMPTION
OF CERTAIN LIABILITIES 
 2.1 Assumed Liabilities. 

(a) Assumed Liabilities. Buyer hereby agrees to assume at the Closing the following items (the “Assumed Liabilities”):

 (1) All obligations under Assumed Contracts arising on or after the Closing Date and $25,000 of the Cure Amount pursuant to the
Modification and Assignment Option Agreement among Introgen Therapeutics, Pope Investments II LLC and the Trustees of Columbia University in the City of New York, New York in the form attached hereto as Schedule 2.1(0(1); 

(2) Any costs or claims associated with any damages related to the removal and transport of the Assets by Buyer or the failure of Buyer to
comply with applicable law related to such removal and transport of the Assets. 
 (b) Excluded Liabilities. Except for those Assumed
Liabilities set forth in Section 2.1(a), at the Closing, Buyer shall not assume, and Sellers shall be solely and exclusively liable with respect to, all other liabilities and obligations of Sellers, including all Cure Amounts not
expressly assumed by Buyer in Section 2.1(a) (such liabilities and obligations being the “Excluded Liabilities”). 

2.2 Further Assurances. Upon the reasonable request of Sellers, at any time and from time to time after the Closing Date,
without further consideration, Buyer shall execute and deliver such further instruments of assumption and take such other actions as Sellers reasonably may require of Buyer to further document or evidence the assumption of the Assumed Liabilities,
including but not limited to the execution of 

  
 5 

 
such instruments as may be requested by any creditor, lessor or any other person whose consent is required to consummate the transactions contemplated by this Agreement. Upon the reasonable
request of Buyer, and upon the Bankruptcy Court’s approval of such request if such approval is required by law, at any time and from time to time after the Closing Date, without further consideration, Sellers agree to execute and deliver such
deeds, bills of sale, assignments or assurances and to take and do any other actions and things to vest, perfect or confirm of record or otherwise in Buyer any and all right, title and interest in, to and under any of the Assets acquired or to be
acquired by the Buyer as a result of, or in connection with, this Agreement. Pending the effective transfer thereof, Sellers agree to hold all rights or entitlements to such Assets in trust for the exclusive benefit of Buyer, provided that Buyer
shall pay, perform and discharge all obligations arising or accruing with respect thereto during the time that the Sellers shall hold such Assets in trust. Sellers agree that when a Liquidating Trustee is appointed, Sellers shall cause the
Liquidating Trustee to assume all obligations of the Sellers under this Agreement that survive the Closing. 
 ARTICLE III 

CONDITIONS TO OBLIGATIONS 

3.1 Conditions to Obligations of Sellers. All obligations of Sellers under this Agreement are subject to the fulfillment,
unless waived in writing at the sole option of Sellers, at or prior to the Closing Date, of each of the following conditions precedent: 

(a) Representations and Warranties. The representations and warranties of Buyer herein contained shall be true and correct as of the
date of this Agreement and shall be true and correct in all material respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct) on and as of the
Closing Date, except that any representation or warranty which by its terms is made as of a specified date shall be true and correct in all material respects as of such specified date (except that where any statement in a representation or warranty
expressly includes a standard of materiality, such statement shall be true and correct) with the same force and effect as though made on and as of said date. 

(b) Covenants. Buyer shall have performed in all material respects all of the obligations and agreements and complied in all material
respects with all of the covenants contained in this Agreement to be performed and complied with by it at or prior to the Closing Date. 

(c) Closing Documents. Sellers shall have received all agreements, certificates, instruments and other documents required to be
delivered by Buyer on the Closing Date pursuant to Section 4.4, and the form and substance of all such agreements, certificates, instruments and other documents shall be reasonably satisfactory to Sellers. 

(d) Absence of Orders; Actions. No Law or Order shall have been enacted, entered, issued, promulgated or enforced by any Governmental
Entity which prohibits or materially restricts the transactions contemplated by this Agreement. 
 (e) Bankruptcy Court Orders. The
Sale Order shall be final and in full force and effect. 
 3.2 Conditions to the Obligations of Buyer: All obligations
of Buyer under this Agreement are subject to the fulfillment, unless waived in writing at the sole option of Buyer, at or prior to the Closing Date, of each of the following conditions precedent: 

(a) Representations and Warranties. The representations and warranties of Seller herein contained shall be true and correct as of the
date of this Agreement and shall be true and correct in all material 

  
 6 

 
respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct) on and as of the Closing Date,
except that any representation or warranty which by its terms is made as of a specified date shall be true and correct in all material respects as of such specified date (except that where any statement in a representation or warranty expressly
includes a standard of materiality, such statement shall be true and correct) with the same force and effect as though made on and as of said date. 

(b) Covenants. Sellers shall have performed in all material respects all of the obligations and agreements and complied in all material
respects with all of the covenants contained in this Agreement to be performed and complied with by Sellers on or prior to the Closing Date. 

(c) Due Diligence Review. 

(1) Buyer shall have completed its due diligence review of the Assets, including verification of all schedules to this Agreement, and be
reasonably satisfied with the results thereof; and 
 (2) any matters discovered in Buyer’s due diligence review and brought to
Sellers’ attention must have been resolved to the reasonable satisfaction of Buyer. 
 (d) Crucell Amendment. Introgen
Therapeutics and Crucell shall have executed an amendment to the Assigned Patents License Agreement entered into as of May 15, 2009 between Introgen Therapeutics and Crucell (the “Crucell License”) in a form that is reasonably
satisfactory to Buyer and that clarifies (1) that the Crucell License covers all the Programs, (2) that if Buyer divides the Assets among different subsidiary or affiliated companies of Buyer after the Closing, that each of those
subsidiary or affiliated companies, and their respective successors, could be granted a sublicense by Buyer under the Crucell License for their particular Programs, and (3) that if Buyer or any of those subsidiary or affiliated companies, or
their respective successors, either (A) hires a third party contractor to manufacture any product resulting from a Program, (B) enters into an agreement with a third party to develop or commercialize any product resulting from a Program,
or (C) transfers to a third party substantially all its assets relating to a product resulting from a Program, they can grant that third party a sublicense under the Crucell License, with the right to grant sublicenses, with respect to such
product. 
 (e) Vivante Negotiations. To the extent that the Vivante Agreement purported to transfer to Vivante certain assets listed
in Schedule 3.2(e) attached hereto, Sellers shall have secured rights to such assets sufficient to transfer such assets to Buyer at Closing. 

(f) Matters Related to Subsidiaries. In the event that a wholly owned direct or indirect subsidiary of any Seller (each a
“Material Subsidiary”) owns, controls or holds assets, materials, properties, rights and/or privileges related directly to the Assets or otherwise necessary for Buyer to develop, obtain regulatory approvals for, manufacture,
commercialize and market the Assets (“Subsidiary Rights”), then either 
 (i) Buyer shall have received
evidence from Sellers satisfactory to Buyer, in its reasonable discretion, that all such Subsidiary Rights held by any such Material Subsidiary have either (1) been terminated, or (2) been completely transferred and assigned prior to
Closing or will be completely transferred and assigned to Buyer at the Closing, in each case without such Material Subsidiary retaining any rights associated therewith and in each case, free and clear of Liens, Claims, interests and Encumbrances,
each as defined in the Sale Order, except for Assumed Liabilities, or 
 (ii) Sellers shall transfer the equity interests in
any such Material Subsidiary to Buyer at Closing, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities. 

  
 7 

 (g) Additional Contracts. Sellers shall have made any filings with the Bankruptcy Court,
obtained any counter-party or other Approvals and taken all actions necessary or appropriate to transfer, assume and assign to Buyer all Additional Contracts designated on each Transfer Notice, if any, pursuant to Section 1.1(c), other
than any Additional Contracts set forth in a Withdrawal of Transfer Notice. 
 (h) Closing Documents. Buyer shall have received all
documents required to be delivered by Sellers on the Closing Date pursuant to Section 4.3. 
 (i) Absence of Orders;
Actions. No Law or Order shall have been enacted, entered, issued, promulgated or enforced by any Governmental Entity which prohibits or materially restricts the transactions contemplated by this Agreement. 

(j) Bankruptcy Court Orders. The Sale Order shall have been modified such that the benefits and protections that inure to Buyer under
the Sale Order will also inure to the benefit of Buyer’s permitted assigns and successors. In addition, the Sale Order or any amendment thereto shall be final and in full force and effect. Further, the Sale Order shall be modified as necessary
to provide for the reimbursement to Buyer by a third party buyer under the terms and conditions set forth in Section 5.4 hereof. 

(k) Approvals and Orders. Sellers shall have made any filings, taken all actions, and obtained any and all other Approvals and Orders
necessary or appropriate under the Bankruptcy Code and the Assumed Contracts for consummation of the sale of the Assets, the assumption by or assignment to the Buyer of the Purchased Contracts, subject to Sellers’ obligations to comply with any
order of the Bankruptcy Court, and shall have provided satisfactory evidence of same to Buyer. 
 ARTICLE IV 

CLOSING 
 4.1 Time
and Place. The Closing shall take place at the offices of Munsch, Hardt, Kopf & Harr, P.C. 600 Congress Ave., Suite 2900, Austin, Texas 78701, two (2) Business Days after the satisfaction or waiver of all conditions to Closing
set forth in Article III hereof (other than those conditions that by their nature cannot be satisfied until the time of Closing, but subject to the satisfaction or waiver of those conditions) or at such other time and place as Sellers and
Buyer may mutually agree (the “Closing Date”). 
 4.2 Closing Transactions. All documents and other
instruments required to be delivered at the Closing shall be regarded as having been delivered simultaneously, and no document or other instrument shall be regarded as having been delivered until all have been delivered. 

4.3 Deliveries by Sellers to Buyer. At the Closing, Sellers shall deliver or cause to be delivered to Buyer: 

(a) the certificate of incorporation (or comparable organizational documents) of each Seller certified by the Secretary of State of the State
of Delaware; 
 (b) a certificate executed by the CRO of each Seller, dated as of the Closing Date, to the effect that the conditions
specified in Section 3.2(a), (b), (e) and (k) are satisfied in all respects; 

  
 8 

 (c) such instruments of transfer and assignment for the Assets that Buyer may request to vest the
Assets in Buyer, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, in accordance with terms of this Agreement; and 

(d) such other instruments and documents as are required by any other provisions of this Agreement or any agreement executed in connection
herewith to be delivered on the Closing Date by Sellers to Buyer. 
 4.4 Deliveries by Buyer to Sellers. At the Closing, Buyer
shall deliver or cause to be delivered to Sellers: 
 (a) the Purchase Price in accordance with the terms of this Agreement; 

(b) a certificate of the secretary or assistant secretary of Buyer certifying to: (i) the certificate of formation (or comparable
organizational documents) of Buyer; (ii) the resolutions of the board of directors (or other governing body) of Buyer approving the execution, delivery and performance of this Agreement, the Transaction Document to which Buyer is a party and
the consummation of the transactions contemplated hereby; and (iii) the incumbency and signatures of the officers of Buyer executing this Agreement and any other certificate or document delivered in connection herewith; 

(c) a certificate executed by the president, a vice president or the treasurer of Buyer, dated as of the Closing Date, to the effect that the
conditions specified in Section 3.1(a) and 3.1(b) are satisfied in all respects; 
 (d) the certificate of formation (or
comparable organizational documents) of Buyer certified by the Secretary of State of its jurisdiction of organization, a certificate of existence or good standing therefrom, as applicable, dated as of a recent date and a “bring-down”
telegram or certificate of good standing from such jurisdiction of organization dated as of a date within three (3) Business Days of the Closing Date; and 

(e) such other instruments and documents as are required by any other provisions of this Agreement or any agreement executed in connection
herewith to be delivered on the Closing Date by Buyer to Sellers. 
 ARTICLE V 

PAYMENT OF PURCHASE PRICE AND SALE/CLOSING 

5.1 Payment of Purchase Price. At the Closing and in consideration for the sale, transfer and assignment of the Assets, Buyer
shall pay to Sellers the Purchase Price. 
 5.2 Allocation of Purchase Price. The Purchase Price and Contingent Royalty
Payments shall be allocated among the Assets in a manner mutually agreeable to Buyer and Seller. Buyer shall prepare such allocation and deliver it to Seller for approval, which approval will not be unreasonably withheld. Buyer and Seller will
utilize the agreed upon allocation in all applicable tax filings. 
 5.3 Deposit. Immediately upon the execution and delivery
of this Agreement, Buyer shall tender to Sellers a deposit in the amount of One Hundred Thirty-Eight Thousand Dollars ($138,000.00) (the “Deposit”) as consideration for Buyer’s option to terminate this Agreement under
Section 8.1(a) and other purposes. The Deposit shall be made payable to Sellers in the form of a wire transfer (wire instructions to be provided upon request) or cashier’s check. At the Closing, the Deposit shall be credited against
the Purchase Price. 

  
 9 

 5.4 Reimbursement of Deposit. Other than as set forth below with respect to a
termination under Section 8.1(f), if this Agreement is terminated for any reason including because the bankruptcy court allows another third party to purchase the Assets, then if either or both of Sellers sell Assets or any part thereof
to one or more third-party purchasers within 365 days of the termination of this Agreement, then the Sellers shall obligate the third-party purchaser(s), as a condition of the sale, to reimburse Buyer for the Deposit and any Patent Funds, any
Storage Costs and any Additional Patent Costs and storage costs paid by Buyer pursuant to Section 6.6 and Section 8.1(c), and this obligation of Sellers shall continue in any subsequent sales or transfers of Assets until the
full amount has been reimbursed to Buyer. If this Agreement is terminated by Sellers pursuant to Section 8.1(f), then the Deposit, any Patent Funds, and Storage Costs and any Patent Costs and storage costs paid by Buyer shall not be
refundable or repaid to Buyer but shall be forfeited by Buyer. 
 ARTICLE VI 

COVENANTS 
 6.1
Access. 
 (a) Each Seller and Buyer agrees that it shall preserve and keep the books and records held by it, its subsidiaries
or its controlled Affiliates relating to the Assets for a period of three (3) years from the Closing Date. Each Seller agrees to take, and to cause any of its subsidiaries or Affiliates to take, such steps as are reasonably necessary to protect
the confidentiality of such books and records during such time period and shall not disclose to any third party any portion thereof which would reasonably be expected to be confidential with respect to the Assets, including without limitation,
procedures relative to Programs, research, studies, test results related to the Programs and Transferred Intellectual Property, without the prior written consent of Buyer. 

(b) Sellers shall give Buyer reasonable access, during normal business hours and upon reasonable prior written notice, including making
available at reasonable times and to a reasonable extent Sellers’ officers and employees to discuss Sellers’ business associated with the Assets with Buyer’s representatives (including representatives of Buyer’s proposed
financiers or lenders) and their counsel, to review and/or photocopy (A) all books, records, accounts and documents of Sellers relating to the assets, properties and operations of its business associated with the Assets including, without
limitation, all computer data files stored, used, held or kept in connection with the operation of its business, and (B) all mailing lists and customer lists used by Sellers in or relating to its business associated with the Assets. Buyer shall
have the right at its own expense to make copies of such materials to the extent that they relate to the operations of Sellers’ business associated with the Assets. Seller agrees to use its reasonable efforts to take or cause to be taken all
action and to assist and cooperate with Buyer in good faith to consummate and make effective the transactions contemplated hereby, including: (a) using Sellers’ reasonable best efforts to provide in a timely manner all materials and
information requested by Buyer to complete its due diligence review and to take all actions reasonably necessary to satisfy the closing conditions, (b) the obtaining of applicable consents, waivers or approvals of any third parties required
under the terms of the Assumed Contracts, (c) the defending of any proceeding challenging this Agreement or the performance of the obligations hereunder, and (d) the execution and delivery of such instruments and the taking of such other
actions as Buyer may reasonably request in order to consummate the terms of this Agreement. 
 (c) For a period of three (3) years from
the Closing Date, Buyer shall give Sellers reasonable access, during Buyer’s normal business hours and upon reasonable prior written notice, to all 

  
 10 

 
books and records of Buyer relating to the operation of Sellers’ business associated with the Assets prior to the Closing Date or to any Excluded Liabilities including, without limitation,
all relevant computer data files stored, used, held or kept in connection with the operation of Sellers’ business, to the extent such files are in Buyer’s possession; provided that as a condition to such access Sellers shall have executed
and delivered a confidentiality agreement reasonably satisfactory to Buyer; provided further that the purpose and extent of such access shall be as necessary in connection with either (i) the contest or defense of any Action brought against
Sellers involving facts, events or circumstances relating to its business associated with the Assets or the Excluded Liabilities, or (ii) the preparation of any Tax return, election, contest or claim for Tax refund or any audit, examination or
proceeding with respect to the Taxes of Sellers. Sellers shall have the right at their own expense to make copies of such materials to the extent that they relate to the operations of Sellers’ business associated with the Assets prior to the
Closing Date or to any Excluded Liabilities. 
 6.2 Insurance. Effective at 12:01 a.m. on the date following the Closing Date,
all insurance coverage maintained by Sellers under which the Assets are insured, including any and all bonds and indemnity obligations, shall be canceled and terminated (except to the extent that they may not, by their terms, be so canceled or
terminated). All premium refunds paid to Sellers relating to such insurance covering the Assets shall be the property of Sellers regardless of whether such refunds are paid on, before or after the Closing Date. 

6.3 Public Announcements. Neither Buyer nor Sellers shall issue any press releases or otherwise make any public statements with
respect to this Agreement or the transactions contemplated hereby without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. At or after the Closing, it is hereby acknowledged and agreed that Buyer
and Sellers may issue press releases or make public statements regarding this Agreement and the transactions contemplated hereby without the prior consent of the other. 

6.4 Updating of Schedules. The parties acknowledge that the schedules attached to this Agreement were prepared in haste and may
need to be updated prior to Closing based on due diligence results. Sellers or Buyer may, at least three (3) days prior to the Closing, deliver updated schedules, if applicable, to reflect changes to the schedules, which schedules must be
reasonably acceptable to the other party, such acceptance not to be unreasonably withheld, prior to Closing. 
 6.5 Purchased
Contracts. 
 (a) Subject to the approval of the Bankruptcy Court and pursuant to the Sale Order, the Purchased Contracts will be
assumed by Sellers and sold and assigned to Buyer (or Buyer’s designee) at the Closing free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, on the Closing Date under
Sections 363(f), 365(a) and 365(b) of the Bankruptcy Code. 
 (b) If after the date hereof (including after the Closing Date), Buyer or
Sellers discover a contract which Buyer in good faith believes should have been treated as an Assumed Contract hereunder and for which Buyer had not been given reasonable opportunity prior to Closing to review and include such contract as an
Assumed Contract and if such contract has not been otherwise assigned to a third party after the Closing, Buyer and Sellers shall take such action and execute such agreements as may be appropriate to effect Buyer’s assumption and Sellers’
assignment of such contract, free and clear of Liens, Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities. 

  
 11 

 6.6 Pre-Closing Covenants. 

(a) Payment of Costs by Buyer. 

(1) Buyer hereby agrees that during the period from the execution of this Agreement by Buyer and Sellers until the earlier of Closing,
November 30, 2009 (unless such date is extended as provided herein), or the termination of this Agreement, Buyer will be responsible for paying all out of pocket costs and expenses of maintaining only the patents listed on
Schedule 6.6(a) attached hereto and incorporated herein by reference which shall be capped at $87,000 in the aggregate (the “Patent Costs”). Buyer will also be responsible for paying the costs of storing the files and
data currently being stored by Sellers at the Greenspoint location for periods beyond October 31, 2009 (or of moving such items and storing them elsewhere for such periods), and the cost of storing the vials included in the Transferred Personal
Property currently being stored with Vivante GMP Solutions, Inc. beyond November 30, 2009 (collectively, the “Storage Costs”). All Storage Costs (and all agreements related thereto including any leases or rental agreements) to
be paid under this Section 6.6(a)(1) or under Section 8.1(c) shall be subject to approval by Buyer, such approval not to be unreasonably withheld or delayed. 

(2) Upon execution of this Agreement by Buyer and Sellers, Buyer will deliver $87,000 in cash or wired funds (the “Patent
Funds”) to Munsch Hardt Kopf & Harr, P.C., counsel to Sellers (“MHKH”), to be held by MHKH and utilized to cover the Patent Costs, some of which were paid prior to the execution of this Agreement by the Sellers, in
which case the Patent Funds will be used to reimburse Sellers for Patent Costs listed on Schedule 6.6(a) and paid by Sellers prior to execution of this Agreement. MHKH will apply the Patent Funds to the Patent Costs as needed to maintain
the patent related Assets. Sellers will provide Buyer with (i) an itemized list of all Patent Costs paid out of the Patent Funds and (ii) proof reasonably satisfactory to the Buyer that the Patent Costs have been paid according to
Schedule 6.6(a). Any Patent Funds not utilized to pay Patent Costs will be refunded to Buyer at Closing or applied to the Purchase Price. 

(3) Buyer and Sellers acknowledge that Storage Costs for Greenspoint have been paid through October 31, 2009, and Storage Costs for
Vivante have been paid through November 30, 2009, and Buyer is not responsible for such Storage costs already paid. Buyer and Sellers further acknowledge and agree that the amount of the Storage Costs for the items at Greenspoint beyond
October 31, 2009, are not currently known, but once they have been determined buyer will promptly pay them subject to the provisions of Section 6.6(a)(1) above. 

(4) Sellers agree that Buyer may, pending Closing and subject to prior notice to Sellers, take such actions as Buyer desires to maintain any
trademarks that are part of the Assets. Buyer acknowledges that Sellers have not generally been taking actions to maintain trademarks and that therefore some trademarks may have lapsed or expired. Buyer agrees to notify Sellers in advance of all
actions taken by Buyer to maintain trademarks prior to Closing. 
 (b) Notification of Certain Matters. Buyer and Sellers
shall promptly notify the other parties to this Agreement of (a) the occurrence or non-occurrence of any fact or event which would be reasonably likely (i) to cause any representation or warranty contained in this Agreement to be untrue or
inaccurate in any material respect at any time from the date hereof to the Closing Date, or (ii) to cause any material covenant, condition or agreement hereunder not to be complied with or satisfied in all material respects, and (b) any
failure of Buyer or Sellers to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder in any material respect. 

(c) Conduct of Business. Except as otherwise contemplated by this Agreement and as Buyer may otherwise consent in writing, until
the Closing: 
 (1) Sellers will not amend, change, terminate or otherwise modify any Purchased Contracts; 

  
 12 

 (2) Sellers will not sell, transfer, mortgage, encumber or otherwise dispose of any of the
Assets; and 
 (3) Sellers will use reasonable efforts to preserve the Assets. 

(d) Approvals and Best Efforts. Each Seller and Buyer will use its commercially reasonable best efforts to obtain as promptly as
practicable all Approvals of any Governmental Entity or other Person required in connection with the consummation of the transactions contemplated by this Agreement. In addition, subject to the terms and conditions herein provided, each Seller and
Buyer covenants and agrees to use its commercially reasonable best efforts to take, or cause to be taken, all action or do, or cause to be done, all things necessary, proper or appropriate to consummate and make effective the transactions
contemplated hereby, to satisfy the conditions in Sections 3.1 and 3.2 and to cause the fulfillment of the parties’ obligations hereunder. 

(e) Bankruptcy Court Approval. 

(1) Each Seller and Buyer acknowledge that Sellers have obtained the Sale Order from the Bankruptcy Court authorizing the sale of the Assets
to Buyer under the terms set forth herein. 
 (2) Sellers shall promptly make any filings, take all actions, and use commercially
reasonable best efforts to obtain any and all other Approvals and Orders necessary or appropriate for consummation of the sale of the Assets or the assumption of the Purchased Contracts, subject to its obligations to comply with any order of the
Bankruptcy Court. 
 (3) In the event an appeal is taken, or a stay pending appeal is requested, from the Sale Order, Sellers shall
immediately notify Buyer of such appeal or stay request and shall promptly provide to Buyer a copy of the related notice of appeal or order of stay. 

(f) Transfer Taxes. In accordance with Section 1146(c) of the Bankruptcy Code, the making or delivery of any instrument of
transfer, including the filing of any deed or other document of transfer to evidence, effectuate or perfect the rights, transfers and interest contemplated by this Agreement, shall be in contemplation of a plan or plans of reorganization to be
confirmed in the Bankruptcy Case, and as such shall be free and clear of any and all transfer Tax, stamp Tax or similar Taxes. Such instruments transferring the Assets to Buyer shall contain the following endorsement: 

“Because this [instrument] has been authorized pursuant to Order of the United States Bankruptcy Court for the Western District of Texas,
Austin Division, in contemplation of a plan of reorganization of the Grantor, it is exempt from transfer taxes, stamp taxes or similar taxes pursuant to 11 U.S.C, 1146(c).” 

6.7 Bankruptcy Filings. From and after the date hereof until the Closing Date, Sellers shall provide Buyer the opportunity to
review and comment reasonably on all documents, motions, orders, filings or pleadings that Sellers file in the Bankruptcy Court which relate to the consummation or approval of the sale of the Assets and this Agreement and will consider all
reasonable comments of Buyer. Further, without the prior written consent of Buyer, the Sellers shall not seek to amend or modify any provision of the Sale Order to effect a change in terms and conditions of the transactions contemplated by this
Agreement which would 

  
 13 

 
reasonably be expected to have a material adverse effect on the Buyer or on the ability of the Sellers and the Buyer to consummate the transaction contemplated hereby. Sellers will also promptly
provide Buyer with facsimile or electronic copies of all pleadings received by or served by or upon the Sellers in connection with the Bankruptcy Case, which, to Sellers’ knowledge, have not otherwise been served on Buyer. 

6.8 Turnover of Payments. In the event that Buyer receives any payment or instrument of payment of any amount included in the
Excluded Assets or any other payment or amount to which Sellers are entitled, Buyer shall deliver the same promptly to Sellers (with endorsement, if necessary, but otherwise in the same form as received) and, until so delivered, hold the same in
trust for Sellers’ benefit and as property of Sellers. In the event that Sellers receive any payment or instrument of payment of any amount included in the Assets or any other payment or amount to which Buyers are entitled, Sellers shall
deliver the same promptly to Buyer (with endorsement, if necessary, but otherwise in the same form as received) and, until so delivered, hold the same in trust for Buyer’s benefit and as property of Buyer. 

6.9 Post-Closing Covenants and Reports. Buyer agrees to remove all Assets from the location where Sellers are keeping them on or
before ten (10) days following Closing. Buyer will arrange for and pay for all shipping and delivery of the Assets, will bear the risk of loss of the Assets as soon as they leave the location Sellers are storing them, and shall be responsible
for insuring the Assets during and after they leave Sellers’ possession. Buyer agrees that it will provide quarterly reports to Sellers detailing all Net Sales for the immediately preceding quarter, and also providing a calculation of the
aggregate Net Sales since the Closing Date (each a “Net Sales Report”). 
 6.10 HIPPA Compliance. Buyer
agrees that it will comply in all respects with all requirements of the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191 (“HIPAA”) in connection with Buyer’s purchase and use of the Assets. It is
specifically agreed that Buyer shall only be responsible for privacy and other HIPPA requirements arising from Buyer’s activities and Buyer shall not be responsible hereunder for privacy or any other HIPPA requirements of any third party
arising before or after the Closing Date. Buyer agrees not to disclose or use any protected health information or other confidential information that is part of the Assets or is received by or disclosed to Buyer in connection with the sale of the
Assets to Buyer, except in compliance with HIPAA and any rules, regulations and laws promulgated under or in connection with HIPAA. Buyer agrees to defend, indemnify and hold Sellers and each Seller’s shareholders, officers, directors,
employees, attorneys, agents, successors and assigns (a “Seller Indemnified Party”), harmless from and against any and all costs, expenses, damages, claims, causes of action, and liabilities arising from or related to any failure of
Buyer to comply with its obligations hereunder. Sellers, for themselves and each other Seller Indemnified Party, acknowledge and agree that Sellers’ sole remedy for the breach of this Section 6.10 shall be limited to seeking
enforcement of the indemnification obligations set forth in the immediately preceding sentence. Any Seller Indemnified Party claiming indemnification under this Section must promptly (i) notify Buyer of any claim asserted against the Seller
Indemnified Party which could give rise to a right of indemnification under this Section 6.10 and (ii) transmit to Buyer a written notice (a “Claim Notice”) describing in reasonable detail the nature of the claim, a
copy of all papers served with respect to that claim (if any), an estimate of the amount of damages attributable to that claim to the extent feasible (which estimate will not be conclusive of the final amount of that claim) and the basis for the
Seller Indemnified Party’s request for indemnification under this Agreement. Failure to promptly deliver a Claim Notice will not relieve Buyer of its obligations to the Seller Indemnified Party with respect to the related claim except to the
extent that the resulting delay is materially prejudicial to the defense of that claim. Within 15 days after receipt of any Claim Notice, Buyer must notify the Seller Indemnified Party providing a Claim Notice whether (i) Buyer disputes its
potential liability to the Seller Indemnified Party under this Section 6.10 with respect to that claim and (ii) whether Buyer desires at the sole cost and expense of Buyer, to control the defense of such claim, or if Buyer desires
to allow Sellers to control the defense of such claim at Buyer’s sole cost and expense. If Buyer elects to control the defense of such claim, then the Seller Indemnified Party may participate in, but not control, any defense or settlement of
any claim controlled by the Buyer pursuant to this Section 6.10 and shall bear its own costs and expenses with respect to such participation. 

  
 14 

 6.11 Audit Rights. Sellers have the right at any time and from time to time, but
not more than twice in a given 12 month period, on at least five (5) days advance notice, to audit and analyze Buyer’s records related to the Assets to verify compliance with this Agreement and the accuracy of any Net Sales Reports. An
independent auditor selected by Sellers will conduct each such audit. The Sellers will pay the auditor’s fees and expenses, unless the audit establishes that there were inaccuracies in the Buyer’s Net Sales Reports that result in an
under-calculation of [***] of Net Sales, in which case Buyer will promptly pay the auditor’s reasonable fees and expenses. If the audit determines that amounts are due hereunder, Buyer will promptly pay such amounts. Buyer may hire a separate
independent auditor to confirm the results of any such audit before paying any amounts alleged to be due pursuant to the audit. In the event that Buyer sells, transfers, assigns or licenses all or part of the Assets to a third party which is not an
Affiliate of Buyer, as a condition of such action Buyer shall require that such third party provide Net Sales information to Sellers until such time as aggregate Net Sales equal $500,000,000, with Seller audit rights similar in all material respects
to those set forth in this Section 6.11. Notwithstanding the foregoing, Buyer shall have no obligation hereunder with respect to (i) the accuracy of any Net Sales information provided by any such third party, or (ii) to pursue
legal or other action against such third party for the enforcement of such audit and reporting provisions unless all costs thereof shall be paid by Sellers. 

ARTICLE VII 

REPRESENTATIONS AND WARRANTIES 

7.1 Sellers. Each Seller, severally and not jointly, represents and warrants the following: 

(a) It is a corporation duly organized and validly existing under the laws of the State of Delaware with all necessary corporate power and
authority to execute, deliver and perform this Agreement 
 (b) The execution, delivery and performance of this Agreement by it and the
other agreements being executed and delivered in connection with this Agreement (the “Transaction Documents”) by it to Buyer have been duly and validly authorized by all necessary corporate action on its part, and this Agreement and
the other Transaction Documents constitute its valid and legally binding obligation, enforceable against it in accordance with their respective terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application now or hereafter in effect affecting enforcement of creditors’ rights generally and (ii) general principles of equity. 

(c) At the Closing, it possesses, and is hereby transferring good and indefeasible title to the Assets to Buyer free and clear of Liens,
Claims, interests and Encumbrances, each as defined in the Sale Order, except for Assumed Liabilities, and with all of the protections afforded by, Section 363 of the Bankruptcy Code and Sellers have not sold, transferred, assigned or licensed,
in whole or in part, any of the Transferred Intellectual Property Rights. 
 (d) The execution and delivery of this Agreement and the other
Transaction Documents to which such Seller is a party and the consummation of the transactions contemplated hereby will not result in any violation, or be in conflict with or constitute, with or without notice or the passage of time, a default under
any provision of such Seller’s certificate of incorporation or bylaws, or any Order or contract to which such Seller is a party or by which it or any of its assets and properties are bound. 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 15 

 (e) Seller has provided true and complete copies of (i) all the Assumed Contracts,
(ii) the asset purchase agreement between Vivante GMP Solutions, Inc. and Sellers, (iii) the patent purchase and license agreements between Crucell Holland B.V. and Introgen Therapeutics and (iv) the Restated p53 and K-ras Agreement
between Aventis Pharmaceuticals Products Inc., Aventis Pharma S.A. and Introgen Therapeutics and to the knowledge of Sellers, there are no other contracts or agreements, written or oral, enforceable or unenforceable, related to any of the agreements
set forth in (i) - (iv) of this Section 7.1(e). 
 (f) To the knowledge of Seller, as used in Seller’s business, none
of the Transferred Intellectual Property Rights infringes upon, misappropriates, or violates any proprietary rights of third parties. To the knowledge of Sellers, no Person has asserted or threatened to assert any claim with respect to the
Transferred Intellectual Property Rights (1) to the effect that the Transferred Intellectual Property Rights, as used in Sellers’ business, infringe or misappropriate, or have infringed or misappropriated, any copyright, patent, trademark,
trade secret or other intellectual property right of any other Person or (2) challenging the ownership, validity, enforceability or effectiveness of any of the Transferred Intellectual Property Rights. To the knowledge of Seller, no Person is
or is suspected of infringing upon, misappropriating of have misappropriated or infringed upon, any copyright, patent, trademark, trade secret or other intellectual property right of any of the Assets. 

7.2 Buyer. Buyer represents and warrants the following: 

(a) Buyer is a limited liability company duly organized and validly existing and in good standing under the laws of the State of Delaware with
all necessary power and authority to execute, deliver and perform this Agreement. 
 (b) The execution, delivery and performance of this
Agreement and the other Transaction Documents by Buyer have been duly and validly authorized by all necessary action on the part of Buyer, and this Agreement and the other Transaction Documents constitute the valid and legally binding obligation of
Buyer, enforceable against Buyer in accordance with their respective terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application now or
hereafter in effect affecting enforcement of creditors’ rights generally and (ii) general principles of equity. 
 (c) The
execution, delivery and performance of this Agreement, the other Transaction Documents to which Buyer is a party and the consummation of the transactions contemplated hereby will not result in any violation or be in conflict with or constitute, with
or without notice or the passage of time and giving of notice, a default under any provision of Buyer’s constituent documents or any Order or contract to which Buyer is a party or its respective assets or properties are bound. 

(d) As of the date of this Agreement, Buyer is not aware of, and has no knowledge of, any other contract, agreement, or document that Buyer
believes should be an Additional Contract, or with respect to which Buyer intends to send a Transfer Notice. 
 ARTICLE VIII 

TERMINATION 
 8.1
Termination. This Agreement may be terminated prior to the Closing and the transactions contemplated hereby may be abandoned in accordance with the following: 

(a) This Agreement may be terminated by Buyer, by written notice to Sellers based on the results of the Buyer’s due diligence on the
Assets pursuant to Section 3.2(c) not being reasonably satisfactory to Buyer, provided that any such notice shall specify the particular due diligence issues resulting in the termination. 

  
 16 

 (b) This Agreement may be terminated at any time by the mutual written consent of Buyer and
Sellers. 
 (c) This Agreement may be terminated by Sellers upon written notice from Sellers to Buyer if the Closing has not taken place on
or prior to November 30, 2009; provided, however, that Sellers may only terminate this Agreement pursuant to this Section 8.1(c) if the failure to close is not the result of a breach by Sellers of any material provision contained in
this Agreement, including but not limited to Section 6.1(b); and further provided, that Buyer will have the option to extend the date in this Section 8.1(c) to December 31, 2009 by providing written notice to Sellers of
Buyer’s desire to extend and Buyer’s agreement to pay the out of pocket costs and expenses necessary to maintain the patents that Buyer desires to acquire. No later than November 27, 2009, Buyer shall deliver to Sellers the
December docket marked to show which patents Buyer desires to maintain and Buyer and Sellers shall work together to agree on the amount of maintenance fees and reasonable legal fees to be paid to Wall (the “Additional Patent
Costs”) and (ii) the Storage Costs through December 31, 2009. In the event Buyer exercises its right to extend under this Section 8.1(c), Buyer shall promptly deliver an amount equal to the Additional Patent Costs (the
“Additional Patent Funds”) in cash or wired funds to MHKH to be held by MHKH and utilized to cover the Additional Patent Costs, and shall pay the Storage Costs through December 31, 2009, MHKH shall apply the Additional Patent
Funds to the Additional Patent Costs as needed to maintain the patent related Assets. Sellers will provide Buyer with (i) an itemized list of all Additional Patent Costs paid out of the Additional Patent Funds and (ii) proof reasonably
satisfactory to the Buyer that the Additional Patent Costs have been paid. Any Additional Patent Funds not utilized to pay Additional Patent Costs will be refunded to Buyer at Closing or applied to the Purchase Price. 

(d) This Agreement may be terminated by Sellers upon written notice from Sellers to Buyer if the Closing has not taken place on or prior to
November 30, 2009; provided, however, that Sellers may only terminate this Agreement pursuant to this Section 8.1(d) if the failure to close is not the result of a breach by Sellers of any material provision contained in this
Agreement, including but not limited to Section 6.1(b), and if all conditions under Section 3.2 (other than Section 3.2(c)(1)) have been satisfied; provided further that if Buyer has notified Sellers of anything
that Buyer has discovered in its due diligence review that has not yet been corrected or resolved to Buyer’s reasonable satisfaction, including specifically, without limitation, any Additional Contracts which have been designated in a Transfer
Notice in accordance with Section 1.1(c) hereof and not yet transferred to Buyer or a Cure Amount has not been agreed upon with a third party or established by the Bankruptcy Court, or an agreement has not been reached between Buyer and
Sellers as to who should pay the Cure Amount or in what proportions, Sellers may not terminate under this provision until such time as the matter has been resolved to Buyer’s reasonable satisfaction. 

(e) This Agreement may be terminated by Buyer or Sellers, upon written notice to the other, if there shall be in effect a non-appealable order
of a court of competent jurisdiction permanently prohibiting the consummation of the transactions contemplated hereby. 
 (f) This Agreement
may be terminated by Sellers if Buyer is in material breach of any material covenant or agreement under this Agreement, or if any representation or warranty of Buyer is not true and correct in all material respects (except that where any statement
in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct), in either case such that the conditions set forth in Sections 3.1(a) and (b) would not be satisfied and
which is not curable or, if curable, is not cured within thirty (30) calendar days after written notice of such breach is given to Buyer by Sellers. 

(g) This Agreement may be terminated by Buyer if Sellers are in material breach of any material covenant or agreement under this Agreement, or
if any representation or warranty of Sellers is not true and correct in all material respects (except that where any statement in a representation or warranty expressly includes a standard of materiality, such statement shall be true and correct),
in either case such that the conditions set forth in Sections 3.2(a) and (b) would not be satisfied and which is not curable or, if curable, is not cured within thirty (30) calendar days after written notice of such
breach is given to Sellers by Buyer. 

  
 17 

 8.2 Status of Agreement after Termination. Upon any termination of this Agreement
pursuant to Section 8.1, this Agreement shall become void and shall have no effect, except for those obligations in Sections 5.3, 5.4, 6.3, 6.8 and 10.4, each which shall survive the termination of
this Agreement in accordance with its terms. 
 8.3 Survival. The representations, warranties, agreements or covenants of the
parties made in this Agreement, and any rights arising out of any breach of any such representation, warranty, agreement or covenant, shall not survive beyond the Closing Date, except for those covenants or agreements of the parties which by their
terms contemplate performance after the Closing Date and the following provisions, all of which shall survive the Closing Date subject to the terms hereof: Sections 1.1(a), 1.1(c), 1.2(b), 1.2(c), 1.4, 2.2, 5.2, 6.1(b), 6.1(c), 6.5(b),
6.6(a) ,6.8, 6.9, 6.10, 6.11, 8.3 and Article X. 
 ARTICLE IX 

CERTAIN DEFINITIONS 
 As
used in this Agreement, the following definitions shall apply: 
 9.1 “Action” means any charge, claim, lawsuit,
complaint, request for investigation, report of alleged violation of law or regulation, or legal proceeding of any nature filed with or made to any Governmental Entity or organization having jurisdiction or authority over Sellers, their assets,
their property or their operations. 
 9.2 “Affiliate” means a Person that directly, or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, a specified Person. 
 9.3
“Agreement” means this Asset Purchase Agreement by and between Buyer and Sellers, as amended or supplemented, together with all schedules attached hereto. 

9.4 “Approval” means any approval, authorization, consent, qualification or registration, or any waiver of any of the
foregoing, required to be obtained from, or any notice, statement or other communication required to be filed with or delivered to, any Governmental Entity or any other Person. 

9.5 “Bankruptcy Code” means 11 U.S.C, 101 et seq., and applicable federal rules of bankruptcy procedure thereunder.

 9.6 “Bankruptcy Court” means the United States Bankruptcy Court for the Western District of Texas, Austin
Division. 
 9.7 “Business Day” means a day that is not a Saturday, Sunday or legal holiday in Austin, Texas. 

  
 18 

 9.8 “Closing” means the closing of the transactions contemplated by this
Agreement. 
 9.9 “Cure Amount” shall have the meaning assigned to such term in the Sale Order. 

9.10 “Expenses” means reasonable attorneys’ and accountants’ fees and expenses, costs of investigation and
all other reasonable out-of-pocket expenses. 
 9.11 “Governmental Entity” means any government or any agency,
bureau, board, commission, court, department, official, political subdivision, tribunal or other instrumentality of any government, whether federal, state or local, domestic or foreign. 

9.12 “Laws” means any law, statute, regulation, rule, ordinance or Order of a Governmental Entity. 

9.13 “Lien” means any mortgage, pledge, deed of trust, hypothecation, lien, security interest, encumbrance, or other
similar restriction, claim or right of others. 
 9.14 “Net Sales” means the revenues actually received by Buyer,
any affiliate of Buyer, any subsequent transferees of any of the Assets, and any sublicensee of any of the foregoing, from all sales of Products anywhere in the world, less deductions for any: (a) credits, allowances, samples, discounts and
rebates actually granted to such customers (including those granted to managed-care entities and government agencies as well as entities that manage patient drug benefits); (b) freight and insurance costs actually paid only if stated on an
invoice; (c) trade, quantity or cash discounts; (d) retroactive price reductions actually given; and (e) sales, value-added and other direct taxes (including customs, duties and other similar governmental charges) incurred directly in
connection with the sales of Products to third party customers and actually paid only if stated on an invoice. In the event that a Product is sold for a single price in combination with another therapeutically active ingredient, or other product or
service which does not constitute a Product under this Agreement if sold separately, Net Sales from such combination sales for purposes of calculating Net Sales under Section 1.2 shall be calculated by multiplying the Net Sales of the
combination product by the fraction A/(A+B), where A is the average gross selling price during the previous calendar quarter of such Product sold separately and B is the average gross selling price during the previous calendar quarter of the
therapeutically active ingredient, or other product or service sold separately. In the event that separate sales of such Product or such additionally therapeutically active ingredient, or other product or service were not made during the previous
calendar quarter, then the Net Sales shall be reasonably allocated between such Product and such active ingredient, or other product or service, based upon their relative values, and if requested by any Seller on behalf of Sellers, Buyer (or its
permitted successors and assigns) and such Seller shall negotiate in good faith and agree on the proper allocation and relative values, such agreement not to be unreasonably withheld by either party. 

9.15 “Order” means any decree, injunction, judgment, order, ruling, writ, quasi-judicial decision or award or
administrative decision or award of any federal, state, local, foreign or other court, arbitrator, tribunal, administrative agency or Governmental Entity to which any Person is a party or that is or may be binding on any Person or its securities,
assets or business. 
 9.16 “Person” means an association, a corporation, an individual, a partnership, a trust or
any other entity or organization, including a Governmental Entity. 
 9.17 “Products” means any product, component
or material the manufacture, use, importation, offer for sale or sale of which would infringe a Valid Claim in the country for which the Product is manufactured, used, imported, offered for sale or sold, where “Valid Claim” means a
claim of an issued and 

  
 19 

 
unexpired patent included within the Transferred Intellectual Property Rights, which has not been held unenforceable, unpatentable or invalid by an unappealed or unappealable order of a court or
other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

9.18 “Purchased Contracts” means (a) the Assumed Contracts and (b) any Transferred Intellectual Property
Rights to the extent treated as executory contracts or unexpired leases under Section 365 of the Bankruptcy Code. 
 9.19
“Tax” means any federal, state, local or foreign income, gross receipts, property, sales, use, license, excise, employment, payroll, withholding or minimum tax, or any other tax, custom, duty, governmental fee or other like
assessment or charge of any kind whatsoever. 
 ARTICLE X 

MISCELLANEOUS 
 10.1
Amendments; Waivers. This Agreement and any schedule attached hereto may be amended only by agreement in writing of Buyer and Sellers. 

10.2 Governing Law. This Agreement and the legal relations between the parties shall be governed by and construed in accordance
with the laws of the State of Texas applicable to contracts made and performed in such State and without regard to conflicts of law doctrines, except to the extent that certain matters are preempted by federal law or are governed by the law of the
jurisdiction of incorporation or formation of the respective parties. 
 10.3 Assignment. The parties acknowledge and agree
that prior to the Closing, Buyer intends to transfer and assign all of its rights and obligations under this Agreement to the Buyer Transferee in accordance with Section 1.2(c) hereof. No assignment of the rights and obligations under
this Agreement or of all or any material portion of the Assets shall be effective unless and until the Buyer Transferee and any subsequent transferees agree in writing in substantially the form attached hereto as Exhibit A to assume all
obligations of the Buyer, or Buyer Transferee, if applicable, under this Agreement and to be bound by this Agreement and the obligations contained herein as if it had been a party hereto (as Buyer) on the date hereof, including without limitation,
the obligation to pay Contingent Royalty Payments resulting from Net Sales. Notwithstanding anything to the contrary in this Section 10.3, after such time as the maximum aggregate Contingent Royalty Payment of $30,000,000 has come due
and been paid to Sellers, any assignment of the rights and obligations under this Agreement or of all or any material portion of the Assets by Buyer, Buyer Transferee or any subsequent transferee will not be subject to the requirements of this
Section 10.3. 
 10.4 Expenses. Except as otherwise specifically provided in this Agreement, each party shall pay
its own expenses incident to the negotiation, preparation and performance of this Agreement and the transactions contemplated hereby, except that Sellers shall pay all costs of securing third-party consents and Approvals with respect to transfers of
the Assets or the Assumed Liabilities. 
 10.5 Parties in Interest. This Agreement shall be binding upon and inure to the
benefit of each party, and nothing in this Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under or by reason of this Agreement. Nothing in this Agreement is intended to
relieve or discharge the obligation of any third person to, or to confer any right of subrogation or action over against, any party to this Agreement. The liquidating trust under the plan of reorganization of Sellers in the Bankruptcy Case (the
“Liquidating Trust”) shall be a third party beneficiary of this Agreement and may enforce all rights of Sellers under this Agreement. 

  
 20 

 10.6 Notices. Any notice, consent, waiver and other communication hereunder must be
in writing and shall be deemed to be duly given when (a) delivered in person, (b) transmitted by confirmed telefax or facsimile or (c) received if sent mailed by certified or registered mail, postage prepaid, return receipt requested,
as follows: 
 If to Sellers, addressed to: 

Introgen Therapeutics, Inc. 

Attn: Mike Ciesla, CRO 
 c/o
Munsch Hardt Kopf & Harr, P.C. 
 600 Congress Avenue, Suite 2900 

Telecopy: (512) 391-6100 

With copy to: 
 Munsch
Hardt Kopf & Harr, P.C. 
 600 Congress Avenue, Suite 2900 

Telecopy: (512) 391-6100 

Attention: Patricia Baron Tomasco, Esq. 

If to Buyer, addressed to: 

Pope Asset Management, LLC 

5100 Poplar Avenue, Suite 805 

Memphis TN 38137 
 Attention:
William Wells 
 Phone: +1 (901) 763-4001 

Fax: +1 (901) 763-4229 

With copy to: 
 Baker
Botts L.L.P. 
 1500 San Jacinto Center 

98 San Jacinto Boulevard 

Telecopy: (512) 322-8377 

Attention: Laura L. Tyson 
 or to such other
address or to such other person as either party shall have last designated by such notice to the other party. 
 10.7
Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable by any court of competent jurisdiction or other Governmental Entity, such provision shall be fully severable and the remaining
provisions of this Agreement shall remain in full force and effect 
 10.8 Headings. The descriptive headings of the articles,
sections and subsections of this Agreement are for convenience only and do not constitute a part of this Agreement. 
 10.9
Counterparts. This Agreement and any amendment hereto or any other agreement (or document) delivered pursuant hereto may be executed in one or more counterparts and by different parties in separate counterparts. All of such
counterparts shall constitute one and the same agreement (or other 

  
 21 

 
document) and shall become effective (unless otherwise therein provided) when one or more counterparts have been signed by each party and delivered to the other party. Facsimile, pdf, or other
electronically delivered signatures shall constitute original signatures for all purposes of this Agreement. 
 10.10 Entire Agreement
and Modification. This Agreement supersedes all prior agreements between the parties with respect to its subject matter and constitutes (along with Transaction Documents) a complete and exclusive statement of the terms of the agreement
between the parties with respect to its subject matter. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 22 

 IN WITNESS WHEREOF, Sellers and Buyer have caused this Agreement to be duly executed on
its behalf as of the date first above written. 
  

			
	SELLERS
	
	INTROGEN THERAPEUTICS, INC.
		
	By:	 	 /s/ Michael L. Ciesla

		
	Name:	 	 Michael L. Ciesla

		
	Title:	 	 Chief Restructuring Officer

	
	INTROGEN TECHNICAL SERVICES, INC.
		
	By:	 	 /s/ Michael L. Ciesla

		
	Name:	 	 Michael L. Ciesla

		
	Title:	 	 Chief Restructuring Officer

	
	BUYER
	
	POPE INVESTMENTS II LLC
		
	By:	 	 /s/ William P. Wells

		
	Name:	 	 William P. Wells

		
	Title:	 	  

 SCHEDULES: 
  

			
	Schedule 1.1(a)(1)	  	Transferred Intellectual Property Assets
		
	Schedule 1.1(a)(2)	  	Assumed Contracts
		
	Schedule 1.1(a)(3)	  	Transferred Personal Property
		
	Schedule 1.1(a)(5)	  	Programs
		
	Schedule 2.1(a)(1)	  	Columbia Modification and Assignment Option Agreement
		
	Schedule 3.2(e)	  	Vivante Transferred Assets
		
	Schedule 6.6(a)	  	Patent Costs

 EXHIBITS: 
  

			
	Exhibit A	  	Joinder Agreement

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	716364	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	2/24/2000	 	Combined Therapeutical Treatment Of Hyperproliferative Disease	 	B. Tocque
									
	EP0800399	 	Belgium	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Switzerland	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Germany	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Denmark	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Spain	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	France	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Great Britain	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Greece	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Ireland	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Italy	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Liechtenstein	 	Aventis Pharma S.A..	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Luxembourg	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0800399	 	Netherlands	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Portugal	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	EP0800399	 	Sweden	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	8/14/2002	 		 	B. Tocque
									
	213015	 	Mexico	 	Aventis Pharma S.A.S.A	 	PAT	 	1/17/1995	 	1/12/1996	 	2/25/2003	 		 	B. Tocque
									
	283989	 	Slovakia	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	1/12/1996	 	7/712004	 		 	B. Tocquc
									
	6262032	 	United States	 	Aventis Pharma S.A.	 	PAT	 	7/17/1997	 	7/17/1997	 	7/17/2001	 		 	B. Tocque
									
	10/412,684	 	United States	 	Aventis Pharma S.A.	 	PAT	 	1/17/1995	 	4/14/2003	 		 		 	B. Tocque
									
	6485958	 	United States	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	12/16/1998	 	11/26/2002	 	Method For Producing Recombinant Adenovirus	 	F. Blanche; J.M. Guillaume
									
	778287	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	1/8/1998	 	11/25/2004	 		 	F. Blanche; Guillaume
									
	2004201075	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	7/25/2001	 	5/26/2005	 		 	F. Blanche; Guillaume
									
	EP0944717	 	Europe	 	Aventis Pharma S.A.	 	PAT	 	7/1/1996	 	6/20/1997	 		 		 	F. Blanche; Guillaume
									
	HU224558	 	Hungary	 	Aventis Pharma S.A.	 	PAT	 	7/1/1996	 	1/8/1998	 	10/28/2005	 		 	F. Blanche; Guillaume

  
 2 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6905862	 	United States	 	Aventis Pharma S.A.	 	PAT	 	9/25/1996	 	10/10/2002	 	6/14/2005	 		 	F. Blanche; Guillaume
									
	6537793	 	United States	 	Aventis Pharma S.A.	 	PAT	 	2/12/1999	 	6/14/2001	 	3/25/2003	 	Method Of Separating Viral Particles	 	F. Blanche; A. Barbot; Cameron
									
	779267	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	2/12/1999	 	7/13/2000	 	1/13/2005	 		 	F. Blanche; A. Barbot; Cameron
									
	EP1141249	 	Europe	 	Aventis Pharma S.A.	 	APP	 	12/13/1998	 	12/30/1999	 		 		 	F. Blanche; A. Barbot; Cameron
									
	696245	 	Australia	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	9/3/1998	 	Defective Recombinant Adenovirus For Gene ‘Therapy Of Tumors	 	Perricaudet; Haddada; E. May
									
	BR1101131	 	Brazil	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	11/4/1997	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Austria	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Belgium	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Switzerland	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E May
									
	EP0695360	 	Germany	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Denmark	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E, May
									
	EP0695360	 	Spain	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E May

  
 3 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0695360	 	France	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Great Britain	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Greece	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Ireland	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Italy	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Liechtenstein	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Luxembourg	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Netherlands	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Portugal	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	EP0695360	 	Sweden	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	7/5/2006	 		 	Perricaudet; Haddada; E. May
									
	220346	 	Hungary	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	8/28/1996	 		 	Perricaudet; Haddada; E. May
									
	8508879	 	Japan	 	Aventis Pharma S.A.	 	APP	 	4/22/1993	 	4/15/1994	 		 		 	Perricaudet; Haddada; E. May

  
 4 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	NO321454B	 	Norway	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	5/15/2006	 		 	Perricaudet; Haddada; E. May
									
	265306	 	New Zealand	 	Aventis Pharma S.A.	 	PAT	 	4/22/1993	 	4/15/1994	 	10/24/1997	 		 	Perricaudet; Haddada; E. May
									
	7163925	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/17/1995	 	5/19/1998	 	1/16/2007	 	P16 Expression Constructs And Their APP In Cancer Therapy	 	X. Jin; J. Roth
									
	6251871B1	 	United States	 	The Board Regents of the University of Texas System	 	PAT	 	7/17/1995	 	2/16/1999	 	6/26/2001	 	P16 Constructs And Their App In Cancer Therapy	 	X. Jin; J. Roth
									
	5229109	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/14/1992	 	7/20/1993	 	Low Toxicity Interleukin-2 Analogues For Use In Immunotherapy	 	E. Grimm; K. Heaton
									
	FP0673257	 	Denmark	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton
									
	EP0673257	 	Italy	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton
									
	EP0673257	 	Liechtenstein	 	The Board of Regents of The University of Texas System	 	PAT	 	4/14/1992	 	4/13/1993	 	10/16/2002	 		 	E. Grimm; K. Heaton

  
 5 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6899870	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/11/1998	 	3/11/1999	 	5/31/2005	 	Induction Of Apoptotic Or Cytotoxic Gene Expression By Adenoviral Mediated Gene Codelivery	 	T. McDonnell; S. Swisher; B. Fang; E. Bruckheimer; M. Sarkiss; L. Ji; J. Roth
									
	762493	 	Australia	 	The Board of Regents of The University of Texas System	 	PAT	 	3/11/1998	 	3/11/1999	 	10/9/2003	 		 	T. McDonnell; S. Swisher; B. Fang; E. Bruckheimer; M. Sarkiss; L. Ji; J. Roth
									
	2379171	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	1/15/2002	 		 	Methods For Treatment Of Hyperproliferative Diseases Using Human Mda-7	 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP1307234	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	5/13/2000	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP200600226 61	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	10/30/2006	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	09/615,154	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	7/15/1999	 	7/13/2000	 		 		 	A. Mhashilkar, B. Schrok; S. Chada
									
	EP1325125	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	7/10/2000	 	7/10/2001	 		 		 	L. Ji: J. Minna; J. Roth; M. Lerman
									
	10/445,718	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	7/10/2000	 	5/27/2003	 		 		 	L. Ji: J. Minna; J. Roth; M. Lerman
									
	2429769	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	5/27/2003	 		 	Methods Of Treatment Involving Human Mda-7	 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh

  
 6 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1404359	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	12/7/2001	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	10/017,472	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	12/7/2001	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	11/746,531	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/7/2000	 	8/30/2007	 		 		 	S. Chada; E. Grimm; A. Mhashilkar; R. Ramesh
									
	2477780	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	8/31/2004	 		 	Methods Of Enhancing Immune Induction Involving Mda-7	 	Chada; Grimm; Mhashilkar; Ramesh
									
	03809886.5	 	China	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 		 	Chada; Pataer; Mhashilkar; Ramesh; Roth; Swisher;
									
	EP1490101	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 	-7	 	S. Chada; A. Pataer; A, Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	2003-574225	 	Japan,	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	11/2/2004	 		 		 	S. Chada; A. Pataer; A. Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	10/378,590	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	3/5/2002	 	3/3/2003	 		 		 	S. Chada; A. Pataer; A. Mhashilkar; R. Ramesh; J. Roth; S. Swisher;
									
	11/000,341	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	12/30/2003	 	11/30/2004	 		 	Methods And Compositions To For Improved Non- Viral Gene Therapy	 	R. Ramesh; B. Gopalan; J. Roth

  
 7 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2006-533032	 	Japan	 	Introgen Therapeutics. Inc.	 	APP	 	5/15/2003	 	5/14/2004	 		 		 	S. Zhang; H. Pham
									
	EP1603943	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	3/3/2003	 	3/2/2004	 		 		 	S. Chada; J. Mumm; R. Ramesh; A. Mhashilkar; Meyn; E. Grimm
									
	10/791,692	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/3/2003	 	3/2/2004	 		 		 	R. Chada; J. Mumm; R. Ramesh; A. Mhashilkar; R. Meyn; E. Grimm
									
	780613	 	Australia	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	8/4/2005	 	Replication-Competent Anti-Cancer Vectors	 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	2378586	 	Canada	 	St. Louis University	 	APP	 	7/12/1999	 	7/12/2000	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Belgium	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Switzerland	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Germany	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Spain	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	France	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	EP1196616	 	Great Britain	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson

  
 8 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1196616	 	Italy	 	St. Louis University	 	PAT	 	7/12/1999	 	7/12/2000	 	11/18/2004	 		 	W. Wold; K. Toth; K. Doronin; A, Tollefson
									
	2001-509486	 	Japan	 	St. Louis University	 	APP	 	7/12/1999	 	1/11/2002	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	09/351,778	 	United States	 	St. Louis University	 	APP	 	7/12/1999	 	7/12/1999	 		 		 	W. Wald; K. Toth; K. Doronin; A. Tollefson
									
	11/249,873	 	United States	 	St. Louis University	 	APP	 	7/12/1999	 	10/13/2005	 		 		 	W. Wold; K. Toth; K. Doronin; A. Tollefson
									
	2,548,220	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	12/1/2003	 	12/1/2004	 		 	Use Of Mda-7 To Inhibit Pathogenic Infectious Organisms	 	S. Chada
									
	11/001,702	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	12/1/2003	 	12/1/2004	 		 		 	S. Chada
									
	11/568,499	 	United States	 	St. Louis University	 	APP	 	4/30/2004	 	10/30/2006	 		 	Oncolytic Adenovirus Armed With Therapeutic Genes	 	S. Chada; W. Wold; L. Zumstein
									
	11/057,710	 	United States	 	St. Louis University	 	APP	 	12/2/2004	 	2/14/2005	 		 	Models For Viral Based Cancer Therapy	 	W. Wold; K. Toth; M. Thomas
									
	To Be Assigned	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	12/22/2004	 	12/22/2005	 		 	Use Of Flexible Bag Container For Viral Production	 	J. Senesac
									
	EP1758615	 	Europe	 	Introgen Therapeutics, Inc.	 	APP	 	6/11/2004	 	6/29/2005	 		 	Combination Treatment Of Cancer With Elicitor Of Gene Product Expression And Gene-Product Targeting Agent	 	J. Roth; G. Schumacher; S. Chada
									
	11/150,521	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	6/11/2004	 	6/10/2005	 		 		 	J. Roth; G. Schumacher; S. Chada
									
	06770317.3	 	Europe	 	University of South Florida	 		 		 		 		 	P53 Vaccine For The Treatment Of Cancers	 	S. Antonia; D. Gabrilovich; S. Chada; K. Menander

  
 9 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	11/433,079	 	United States	 	University of South Florida	 	APP	 	5/12/2005	 	5/12/2006	 		 		 	S. Antonia; D. Gabrilovich; S. Chada; K.
									
	PCT/US 06/18 592	 	World	 	University of South Florida	 	PCT	 	5/12/2005	 	5/12/2006	 		 		 	S. Antonia D.; Gabrilovich; S. Chada; K. Menander
									
	2006206267	 	Australia	 	Introgen Therapeutics, Inc.	 	APP	 	1/2112005	 	1/20/2006	 		 	Topical Administration Permitting Prolonged Exposure Of Target Cells To Therapeutic And Prophylactic Viral Vectors	 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Canada	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	China	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Europe	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 	6/29/1905	 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	India	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Japan	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Korea	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang

  
 10 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	New Zealand	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Russia	 	Introgen Therapeutics, Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
	11/336,664	 	United States	 	Introgen Therapeutics Inc	 	APP	 	1/21/2005	 	1/20/2006	 		 		 	P. Clarke; S. Chada, K. Menander; R. Sobol; S. Zhang
									
		 	Canada	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	China	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	India	 	The Board of Regents of the University of Texas System and Introgen Therapeutics. Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt

  
 11 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Japan	 	The Board of Regents of the University of Texas System and Introgen Therapeutics. Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
		 	Russia	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
	11/349,727	 	United States	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2005	 	2/8/2006	 		 		 	S. Chada; K. Hunt
									
	EP1827487	 	Europe	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc	 	APP	 	11/17/2004	 		 	2007	 	Cancer Immunotherapy Incorporating P53	 	M. Cristofanilli; S. Krishnamurthy; K. Menander; G. Hortobagyi
									
	11/281,922	 	United States	 	The Board of Regents of the University of Texas System and Introgen Therapeutics, Inc	 	APP	 	11/17/2004	 	11/17/2005	 		 		 	M. Cristofanilli; S. Krishnamurthy; K. Menander; G. Hortobagyi
									
	11/559,227	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/12/2005	 	11/13/2006	 		 	Methods for the Production and Purification of Adenoviral Vectors	 	S. Zhang,; H. Pham; P. Clarke

  
 12 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	PCT/US06/08 0847	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	11/12/2005	 	11/13/2006	 		 		 	S. Zhang; H. Pham; P. Clarke
									
	11/668,981	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	1/30/2006	 	1/30/2007	 		 	Prognostic Factors For Anti-Hyperproliferative Disease Gene Therapy	 	R Sobol; S. Chada; L. Zumstein; E. Cvitkovic; K. Menander
									
	PCT/US07/06 1320	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	1/30/2006	 	1/30/2007	 		 		 	R. Sobol; S. Chada; L. Zumstein; E. Cvitkovic; K. Menander
									
	11/748,826	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	5/15/2006	 	5/15/2007	 		 	Methods And Compositions For Protein Production Using Adenoviral Vectors	 	S. Zhang; H. Pham; P. Song; M. Zheng; P. Clarke
									
	PCT/US07/06 8977	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	5/15/2006	 	5/15/2007	 		 		 	S. Zhang; H. Pham; P. Song; M. Zheng; P. Clarke
									
	11/672,896	 	United States	 	The Board of Regents of The University of Texas System and Introgen Therapeutics, Inc.	 	APP	 	2/8/2006	 	2/8/2007	 		 	Compositions and Methods Involving Gene Therapy and Proteasome Modulation	 	R. Ramesh; S. Chada
									
	PCT/US07/06 1883	 	World	 	The Board of Regents of The University of Texas System and Introgen Therapeutics, Inc.	 	PCT	 	2/8/2006	 	2/8/2007	 		 		 	R. Ramesh; S. Chada
									
	11/764,719	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	6/16/2006	 	6/16/2007	 		 	Compositions And Methods Related To Adenovirus Based Delivery Of Antigens	 	P. Clarke
									
	PCT/US07/07 1490	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	6/16/2006	 	6/16/2007	 		 		 	P. Clarke

  
 13 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	11/741,594	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	4/28/2006	 	4/27/2007	 		 	Compositions and Methods Involving MDA-7 for the Treatment of Cancer	 	R. Ramesh
									
	PCT/US07/06 7691	 	World	 	The Board of Regents of The University of Texas System	 	PCT	 	4/28/2006	 	4/28/2007	 		 		 	R. Ramesh
									
		 	Australia	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 	Bioactive Fus1 Peptides and Nanoparticle-Polypeptide Complexes	 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	3/14/2005	 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	China	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	India	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth

  
 14 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
		 	Russia	 	The Board of Regents of The University of Texas System	 	APP	 		 	9/14/2007	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
	11/375,544	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/14/2005	 	3/14/2006	 		 		 	J. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth
									
	PCT/US2008/055507	 	World	 	Introgen Therapeutics, Inc.	 	PCT	 	3/1/2007	 	2/29/2008	 		 		 	S. Zhang and E. Onishi
									
		 	Australia	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 	Methods And Composition Related To In Vivo Imaging Of Gene Expression	 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Canada	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B, Fang; L. Ji; D. Yang
									
		 	China	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang

  
 15 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Europe	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; 13. Fang; L. Ji; D. Yang
									
		 	India	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Japan	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Korea	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kundra; B. Fang; L. Ji; D. Yang
									
		 	Russia	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kendra; B. Fang; L. Ji; D. Yang
									
	11/909,073	 	United States	 	The Board of Regents of the University of Texas System	 	APP	 	3/9/2005	 	9/9/2007	 		 		 	V. Kendra; B. Fang; L. Ji; D. Yang
									
	6017524	 	United States	 	The Board of Regents of The University of Texas System; NIH	 	PAT	 	3/6/1991	 	10/13/1992	 	1/25/2000	 	Methods And Compositions For Retroviral Vector Mediated Transduction	 	J. Roth; T. Mukhopadyay; M. Tainsky

  
 16 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6,998,117	 	United States	 	The Board of Regents of The University of Texas System; NIH	 	PAT	 	3/6/1991	 	6/2/1995	 	2/14/2006	 		 	J. Roth; T. Mukhopadyay; M. Tainsky
									
	6436700	 	United States	 	The Board of Regents of the University of Texas System	 	PAT	 	3/6/1991	 	12/7/1992	 	8/20/2002	 	Anti-Sense K-Ras	 	J. Roth; T. Mukhopadhyay; M. Tainsky
									
	6410010	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/29/1993	 	6/25/2002	 	Recombinant p53 adenovirus methods and compositions	 	W. Zhang; J. Roth
									
	698437	 	Australia	 	The Board of Regents of the University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	2/11/1999	 		 	W. Zhang; J. Roth
									
	P19408179-4	 	Brazil	 	The Board of Regents of the University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	2174556	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	ZL94194354.2	 	China	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	2/27/2002	 		 	W. Zhang; J. Roth

  
 17 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	288790	 	Czech Republic	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	7/4/2001	 		 	W. Zhang; J. Roth
									
	EP0725791	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	222981	 	Hungary	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	4/5/2004	 		 	W. Zhang; J. Roth
									
	JP 2003265193	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	10-1996-0702193	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	10-2005-7005235	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	275356	 	New Zealand	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	4/15/1998	 		 	W. Zhang; J. Roth

  
 18 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	186151	 	Poland	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	2222600	 	Russia	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	2222600	 	Russia	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	3/23/2004	 		 	W. Zhang; J. Roth
									
	PP509-96	 	Slovakia	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/28/1994	 		 		 	W. Zhang; J. Roth
									
	73265	 	Ukraine	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/28/1994	 	7/15/2005	 		 	W. Zhang; J. Roth
									
	6905873	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	4/2/1996	 	6/14/2005	 		 	W. Zhang; J. Roth
									
	6511847	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	9/21/2000	 	1/28/2003	 		 	W. Zhang; J. Roth

  
 19 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6830749	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	6/25/2002	 	12/14/2004	 		 	W. Zhang; J. Roth
									
	11/251,111	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	10/13/1992	 	10/14/2005	 		 		 	W. Zhang; J. Roth
									
	7033750	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	6/11/2002	 	4/25/2006	 		 	W. Zhang; J. Roth
									
	EP0754237	 	Europe	 	The Board of Regents of the University of Texas System	 	APP	 	4/4/1994	 	4/4/1995	 		 	An adenovirus supervector system	 	W. Zhang; J. Roth
									
	7,252,989	 	United States	 	The Board of Regents of the University of Texas System	 	PAT	 	4/4/1994	 	4/4/1994	 	8/7/2007	 		 	W. Zhang; J. Roth
									
	6143290	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/29/1993	 	4/7/1994	 	11/7/2000	 	Tumor regression by adenovirus expression of wild-type p53	 	W. Zhang; J. Roth
									
	5747469	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	4/25/1994	 	5/5/1998	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub

  
 20 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
		 	Brazil	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	695 35 684.4-08	 	Germany	 	The Board of Regents of The University of Texas System	 		 	3/6/1991	 	1/9/2008	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	JP 2003277272	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	1996 4527	 	Norway	 	The Board of Regents of The University of Texas System	 	APP	 	3/6/1991	 	4/24/1995	 		 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	6627189	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	7/17/1995	 	9/30/2003	 	Inhibition Of Cellular Proliferation Using Ras Antisense Molecules	 	J. Roth; T. Mukhopadhyay; M. Tainsky
									
	6740320	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	6/2/1995	 	6/2/1995	 	5/24/2004	 	Recombinant p53 adenovirus methods and compositions	 	W. Zhang; J. Roth
									
	6482803	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	9/1/1995	 	9/1/1995	 	11/19/2002	 	Modification of mutated p53 gene in tumors by retroviral delivery of ribozyme A	 	J. Roth; D. Cai; T. Mukhopadhyay

  
 21 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	5958892	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/30/1996	 	7/30/1996	 	9/28/1999	 	2-methoxyestradiol-induced apoptosis in cancer cells	 	T. Mukhopadhyay; J. Roth
									
	10-508981	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	7/30/1996	 	7/24/1997	 		 		 	T. Mulchopadhyay; J. Roth
									
	6133416	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	8/23/1996	 	8/22/1997	 	10/17/2000	 	Inhibition of cell growth by an anti-proliferative factor	 	D. Wilson; M. Lapadat-Tapolsky; T. Timmons, J. Lee; B. Almond; J. Roth
									
	6054467	 	United States	 	Introgen Therapeutics, Inc.	 	PAT	 	7/5/1996	 	7/5/1996	 	4/25/2000	 	Down-regulation of DNA repair to enhance sensitivity of p53 mediated suppression	 	R. Gjerset
									
	505400/1998	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	7/5/1996	 	7/2/1997	 		 		 	R. Gjerset
									
	6110744	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	11/12/1997	 	8/29/2000	 	Diminishing viral expression by promoter replacement	 	B. Fang; J. Roth
									
	6630344	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	8/29/2000	 	10/7/2003	 		 	B. Fang; J. Roth
									
	7244671	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	11/13/1996	 	10/2/2003	 	7/17/2007	 		 	B. Fang; J. Roth

  
 22 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1724350	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	5/9/2006	 		 		 	G. Clayman
									
	3588048	 	Japan	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	1998-0704074	 	Korea	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	P-327009	 	Poland	 	The Board of Regents of The University of Texas System	 	PAT	 	11/30/1995	 	11/27/1996	 	3/31/2003	 		 	G. Clayman
									
	08/758,033	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	11/27/1996	 		 		 	G. Clayman
									
	09/968,958	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	10/1/2001	 		 		 	G. Clayman
									
	11/200,527	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	8/9/2005	 		 		 	G. Clayman

  
 23 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	10/395,864	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	11/30/1995	 	3/24/2003	 		 		 	G. Clayman
									
	6479285	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/2/1997	 	7/1/1998	 	11/12/2002	 	p53 as a regulator of cell differentiation	 	P. Vize; J. Wallingford
									
	6797702	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/25/1994	 	8/26/1997	 	9/28/2004	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	7109179	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	4/25/1994	 	2/23/2004	 	9/19/2006	 		 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang: L. Owen-Schaub
									
	11/348,506	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	4/25/1994	 	2/6/2006	 		 	Grimm; T.	 	J. Roth; T. Fujiwara; E.A. Mukhopadhyay; W. Zhang; L. Owen-Schaub
									
	6069134	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	3/6/1991	 	10/17/1997	 	5/30/2000	 	Methods and compositions comprising DNA damaging agents and p53	 	J. Roth; T. Fujiwara; E.A. Grimm; T. Mukhopadhyay; W. Zhang: L. Owen-Schaub
									
	767880	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	3/16/1998	 	9/29/2000	 	3/11/2004	 	Multigene vectors	 	B. Almond; D. Wilson; S. Chada; L. Zumstein
									
	2323112	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	3/16/1998	 	9/14/2000	 		 		 	B. Almond; D. Wilson; S. Chada; L. Zumstein
									
	732703	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	8/9/2001	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho

  
 24 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2272820	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	97181254.3	 	China	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	523965/1998	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	503701	 	Korea	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	7/18/2005	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	1999 2398	 	Norway	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	11/20/1997	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	335497	 	New Zealand	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	11/20/1997	 	4/5/2001	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho
									
	2350890	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	11/16/1999	 		 		 	Z. Wu; S. Zhang
									
	11/837,219	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	8/10/2007	 		 		 	Z. Wu; S. Zhang
									
	11/837,269	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	11/16/1998	 	8/10/2007	 		 		 	Z. Wu; S. Zhang
									
	6429298	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1998	 	10/13/1999	 	8/6/2002	 	Assays for identifying functional alterations in the p53 tumor suppressor	 	A. Ellington; I. Matsumura
									
	09/422,911	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	10/21/1998	 	10/21/1999	 		 	Augmentation of cell growth inhibition by enhancement of intercellular communication	 	D. Frank; T. Liu; D. Wilson; G. Clayman

  
 25 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP1165144	 	Europe	 	Vanderbilt University	 	APP	 	3/15/1999	 	3/15/2000	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	11/025,796	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	12/29/2004	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	11/269,112	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	11/8/2005	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	10/216,346	 	United States	 	Vanderbilt University	 	APP	 	3/15/1999	 	8/9/2002	 		 		 	D. Gabrilovich; D. Carbone; S. Chada; A. Mhashilkar
									
	775579	 	Australia	 	Introgen Therapeutics, Inc.	 	PAT	 	11/20/1996	 	6/28/2001	 	11/18/2004	 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho; S. Gallagher
									
	2353787	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/20/1996	 	5/29/2001	 		 		 	S. Zhang; C. Thwin; Z. Wu; T. Cho; S. Gallagher
									
	09/575,473	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	5/24/1999	 	5/24/2000	 		 	Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases	 	R. Ramesh; J. Roth; T. Saeki; D. Wilson
									
	EP1754488	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	5/24/1999	 	5/9/2006	 		 		 	R. Ramesh; J. Roth; T. Saeki; D. Wilson
									
	6410029	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	7/30/1996	 	7/9/1999	 	6/25/2002	 	2-methoxyestradiol-induced apoptosis in cancer cells	 	T. Mukhopadhyay; J. Roth

  
 26 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6805858	 	United States	 	The Board of Regents of The University of Texas System	 	PAT	 	10/13/1992	 	10/6/1999	 	10/19/2004	 	Methods For The Administration Of Adenovirus P53	 	W. Zhang; J. Roth
									
	2002248341	 	Australia	 	The Board of Regents of The University of Texas System	 	PAT	 	1/11/2001	 	1/9/2002	 	2/26/2007	 	Antihelminthic drugs as a treatment for hyperproliferative diseases	 	T. Mukhopadhyay; J. Roth
									
	2434654	 	Canada	 	The Board of Regents of The University of Texas System	 	APP	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	EP1425012	 	Europe	 	The Board of Regents of The University of Texas System	 	AP P	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	10/043,877	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	1/11/2001	 	1/9/2002	 		 		 	T. Mukhopadhyay; J. Roth
									
	EP1496979	 	Europe	 	The Board of Regents of The University of Texas System	 	APP	 	3/22/2002	 	3/24/2003	 		 		 	L. Ji; J. Roth
									
	11/746,531	 	United States	 	The Board of Regents of The University of Texas System	 	APP	 	3/22/2002	 	5/9/2007	 		 		 	L. Ji; J. Roth
									
	10/747,798	 	United States	 	Introgen Therapeutics, Inc.	 	APP	 	12/27/2002	 	12/29/2003	 		 	p53 treatment of papillomavirus and carcinogen transformed cells in hyperplastic leisions	 	G. Yoo

  
 27 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	5643761	 	United States	 	Columbia University	 	PAT	 	10/27/1993	 	10/27/1993	 	7/1/1997	 	Method for generating a subtracted eDNA library and uses of the generated library	 	P. Fisher; H. Jiang
									
	6720408	 	United States	 	Columbia University	 	PAT	 	10/27/1993	 	12/23/1998	 	4/13/2004	 		 	P. Fisher, H. Jiang
									
	10/417,827	 	United States	 	Columbia University	 	APP	 	10/27/1993	 	4/17/2003	 		 		 	P. Fisher; H. Jiang
									
	695540	 	Australia	 	Columbia University	 	PAT	 	10/27/1993	 	10/24/1994	 	11/26/1998	 		 	P. Fisher; H. Jiang
									
	2174354	 	Canada	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	98115996.5	 	Hong Kong	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	07-512754	 	Japan	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	702185/1996	 	Korea	 	Columbia University	 	APP	 	10/27/1993	 	10/24/1994	 		 		 	P. Fisher; H. Jiang
									
	5710137	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	8/16/1996	 	1/20/1998	 	Use of a melanoma differentiation associated gene (MDA-7) for inducing apoptosis of a tumor cell	 	P. Fisher
									
	6355622	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	2/16/1999	 	3/12/2002	 		 	P. Fisher
									
	6855686	 	United States	 	Columbia University	 	PAT	 	8/16/1996	 	11/21/2001	 	2/15/2005	 		 	P. Fisher
									
	727735	 	Australia	 	Columbia University	 	PAT	 	8/16/1996	 	8/15/1997	 	4/5/2001	 		 	P. Fisher

  
 28 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	2263750	 	Canada	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	97197914.6	 	China	 	Columbia University	 	PAT	 	8/16/1996	 	8/15/1997	 	9/15/2004	 		 	P. Fisher
									
	EP957941	 	Europe	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	510102/98	 	Japan	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	10-19999-7002342	 	Korea	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	991582	 	Mexico	 	Columbia University	 	APP	 	8/16/1996	 	8/15/1997	 		 		 	P. Fisher
									
	334034	 	New Zealand	 	Columbia University	 	PAT	 	8/16/1996	 	2/3/1999	 	2/8/2001	 		 	P. Fisher
									
	2496918	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	8/28/2002	 	8/27/2003	 		 	Chromatographic methods for adenovirus purification	 	J. Senesac
									
	688839	 	Australia	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	7/2/1998	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	2177827	 	Canada	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	5/30/1996	 		 		 	M, Kiefer; P. Barr
									
	EP0731636	 	Belgium	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr

  
 29 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	EP0731636	 	Germany	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Spain	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	France	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Great Britain	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Greece	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Ireland	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Italy	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer, P. Barr
									
	EP0731636	 	Luxembourg	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr
									
	EP0731636	 	Monaco	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	11/30/1994	 	1/11/2006	 		 	M. Kiefer; P. Barr

  
 30 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	F1962247	 	Finland	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	11/30/1994	 		 		 	M. Kiefer; P. Barr
									
	NO962188	 	Norway	 	LXR Biotechnology, Inc.	 	APP	 	11/30/1993	 	11/30/1994	 		 		 	M. Kiefer; P. Barr
									
	6627190	 	United States	 	St. Louis University	 	PAT	 	7/12/1999	 	9/19/2001	 	9/30/2003	 	Recombinant adenovirus vectors that are replication competant in tert-expressing cells	 	W. Wold; K. Toth, K. Doronin; A. Tollefson; M. Kuppuswamy
									
	2005305347	 	Australia	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 	A novel method for the production and purification of adenoviral vectors	 	H. Pham; S. Zhang; P. Clarke
									
	2,586,107	 	Canada	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	20058004233 4.4	 	China	 	Introgen Therapeutics, Inc..	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	2007-540297	 	Japan	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pham; S. Zhang; P. Clarke
									
	10-2007-7012333	 	Korea	 	Introgen Therapeutics, Inc.	 	APP	 	11/3/2004	 	7/22/2005	 		 		 	H. Pharr; S. Zhang; P. Clarke
									
	697088	 	Australia	 	Sidney Kimmel Cancer Center	 	PAT	 	4/29/1994	 	4/28/1995	 	9/24/1998	 	Enhancing the Sensitivity of Tumor Cells to Therapies	 	R. Gjerset; R. Sobol
									
	2189032	 	Canada	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	11/9/1995	 		 		 	R. Gjerset; R. Sobol
									
	9512554	 	Japan	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	4/28/1995	 		 		 	R. Gjerset; R. Sobol

  
 31 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	97702915	 	Korea	 	Sidney Kimmel Cancer Center	 	APP	 	4/29/1994	 	4/28/1995	 		 		 	R. Gjerset; R. Sobol
									
	6015687	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	1/18/2000	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	5998131	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	10/10/1997	 	12/7/1999	 	Screening Methods For The Identification Of Compounds Capable Ofabrogating Bak-Bhrfi Protein Interactions	 	M. Kiefer; P. Barr
									
	6586395	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	7/1/2003	 	Novel Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	7108989	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	3/1/2002	 	9/19/2006	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	6015687	 	United States	 	LXR Biotechnology, Inc.	 	PAT	 	11/30/1993	 	6/6/1995	 	6/23/1998	 	Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof	 	M. Kiefer; P. Barr
									
	5770443	 	United States	 	LXR Biotechnology	 	PAT	 	11/30/1993	 	6/6/1995	 	6/23/1998	 		 	M. Kiefer; P. Barr
									
	6903195	 	United States	 	Tanox, Inc.	 	PAT	 	11/30/1993	 	8/7/2000	 	6/7/2005	 	Methods And Compositions For Detecting Cdn Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	11/082,485	 	United States	 	Tanox, Inc.	 	APP	 	11/30/1993	 	3/16/2005	 		 	Methods And Compositions For Detecting Cdn Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr
									
	1139871	 	China	 	LXR Biotechnology	 	APP	 	11/30/1993	 	11/30/1994	 		 	Novel Apoptosis-Modulating Proteins, Dna Encoding The Proteins And Methods Of Use Thereof	 	M. Kiefer; P. Barr
									
	9509567	 	Japan	 	Tanox, Inc	 	APP	 	11/30/1993	 	11/30/1994	 		 	Methods Of Screening For Therapeutic Agents Using M. Novel Apoptosis-Modulating Proteins	 	M. Kiefer; P. Barr

  
 32 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	6413544	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	10/4/1999	 	7/2/2002	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	6770291	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	11/2/2001	 	8/3/2004	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	7,001,614	 	United States	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	4/15/2004	 	2/1/2006	 	Novel Liposomes For Increased Systemic Delivery	 	N. Smyth-Templeton; G. Pavlakis
									
	2263705	 	Canada	 	Department Of Health And Human Services	 	App	 	8/19/1996	 	8/1/1997	 		 	Novel Sandwich Liposome Complexes Comprising A Biologically Active Agent	 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Switzerland	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Germany	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	France	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Great Britain	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Italy	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis

  
 33 

 Schedule 1.1(a)(i) 

 

																	
	 PAT/APP NO.
	 	 COUNTRY
	 	 OWNER
	 	 TYPE
	 	 EARLIEST
PRIORITY
DATE
	 	 FILING
DATE
	 	 ISSUE

DATE
	 	 TITLE
	 	 INVENTOR

									
	Ep0955999	 	Liechtenstein	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	 5/12/2001
	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Monaco	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	Ep0955999	 	Sweden	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	5/12/2001	 		 	Nav N. Smyth-Templeton; G. Plakis
									
	730771	 	Australia	 	Department Of Health And Human Services	 	Pat	 	8/19/1996	 	8/1/1997	 	6/28/2001	 		 	N. Smyth-Templeton; G. Pavlakis
									
	2000516630	 	Japan	 	Department Of Health And Human Services	 	App	 	8/19/1996	 	8/1/1997	 		 		 	N. Smyth-Templeton; G. Pavlakis

  
 34 

 Schedule 1.1(a)(2) Assumed Contracts 

Patent and Technology License Agreement between Introgen Therapeutics and the Board of Regents, dated July 20, 1994 (with all subsequent amendments,
schedules and attachments thereto) 
 Amended and Restated License Agreement between Introgen Therapeutics, Columbia University and Genquest, Inc. dated
July 18, 1997 
 Exclusive License Agreement between Corixa Corporation, Chinook Corporation and Introgen Therapeutics, Inc. dated July 19, 1999

 Milestone Extension Agreement between Trustees’s of Columbia University, Corixa Corporation and Introgen Therapeutics, Inc. dated August 12,
2001 
 Milestone Extension Agreement between Trustees’s of Columbia University, Corixa Corporation and Introgen Therapeutics, Inc. dated
August 12, 2001 
 Sponsored Research Agreement between Introgen Therapeutics and Oregon Health & Science University, dated September 31,
2007 
 Collaboration and License Agreement between Introgen Therapeutics and ViRx, dated March 7, 2002 

Research Agreement between Introgen Therapeutics and the Board of Regents for the University of Nebraska, dated October 1, 2007 

Patent License Agreement between Introgen Therapeutics and the National Institute of Health, dated September 22, 1998 

CRADA No. 02177 between Introgen Therapeutics and the National Institute of Health, dated March 22, 2007 

Clinical Investigation Agreement between Introgen Therapeutics and the University of Miami, dated May 5, 2000 

Patent License Agreement between Introgen and the University of Iowa Research Foundation, dated April 16, 1997 

 Schedule 1.1(a)(3) Transferred Personal Property Assets 

 

	1.	Advexin Vials: 

 MVB INVENTORY 
  

									
	 Description
	  	Lot No.	  	Part No.	  	Total No.
of Vials	 
	 Ad5CMV p53 MAG MVB I
	  	0048-0009	  	8.50013	  	 	5	  
	 Ad5CMV p53 INT MVB
	  	01698004
 001606
	  	08-00003
 08-00003
	  	 	36 39	  
	 Ad5CMV p53 INT WVB
	  	08198001	  	08-00004	  	 	697	  
	 Ad-MDA7 MVB
	  	MV241001	  	08-00049	  	 	7	  
	 INGN 007 (VRX-007) Virus Stock
	  	004710	  	08-00051	  	 	8	  
	 INGN 007 MVB
	  	MV007007	  	08-00052	  	 	93	  
	 INGN 201 WVB (Wave Process)
	  	WV201001	  	08-00059	  	 	200	  
		  		  		  	  
	  
	 
	 SUBTOTAL
	  		  		  	 	1,085	  
		  		  		  	  
	  
	 

 DP INVENTORY 
  

									
	 Description
	  	Lot No.	  	Part No.	  	Total No.
of Vials	 
	 INGN 201 (ADVEXIN)
	  	B1189801
B2159801
B1489901
B1839901
201-02-1-005	  	10-00007
10-00007
10-00007
10-00007
10-00007	  	 
 
 
 
 	147
538
16
693
108	  
  
  
  
  
	 Advexin (Ad5CMV-p53)- Quarantined, Consistency Batches
	  	P201004
P201005	  	10-00007
10-00007	  	 
  
	21
 86
	  
   

	 INGN 201 (WAVE Process)
	  	P201001	  	10-00032	  	 	1255	  
	 INGN 241
	  	P241001	  	10-00030	  	 	50	  
	 INGN 007
	  	P007007	  	10-00031	  	 	952	  
		  		  		  	  
	  
	 
	 SUBTOTAL
	  		  		  	 	3,866	  
		  		  		  	  
	  
	 
	 TOTAL
	  		  		  	 	4,951	  
		  		  		  	  
	  
	 

  

	2.	Support Data for Transferred Intellectual Property Rights, including all available: 

  

	 	a)	Clinical Data; 

  

	 	b)	Regulatory Data; and 

  

	 	c)	Radiological Scans and Unused Tissue Samples 

  

	 	d)	1 Terabyte external hard drive of documentation related to Transferred Intellectual Property 

 Schedule 1.1(a)(5) 

Programs are therapeutic products comprising nucleic acid constructs to express, promote or enhance expression of the following proteins or variants thereof:

 P53 
 MDA-7 

ADP Vectors comprising a DNA or a nucleotide construct, that expresses or promotes the expression of an E3 11.6K( protein or analog, homologue, variant
or derivative of such protein, and a viral vector that is replication competent in at least some cells, alone or in combination with other subject matter. It is understood that an ADP Vector may, in addition, include other subject matter, such as a
p53 gene or another gene construct. 
 It is understood the Programs include Advexin, INGN 225, INGN 241, INGN 007 and other products described above
including diagnostic, prognostic and predictive biomarkers of products’ efficacy and toxicity. 

 MODIFICATION AND ASSIGNMENT OPTION AGREEMENT 

COLUMBIA UNIVERSITY — INTROGEN THERAPEUTICS — POPE INVESTMENTS 

MDA — 7 GENE 
 This
Milestone Extension and Assignment Option Agreement (the “Agreement”) is dated as of             , 2009 (the “New Effective Date”) and will be effective as
of the later of (i) date the Bankruptcy Court enters a final order (“Order”) authorizing the assumption and assignment of the Exclusive License Agreement to Pope and (ii) upon Columbia’s receipt of the Cure Amount, and is by
and among: The Trustees of Columbia University in the City of New York, New York (“Columbia”); Introgen Therapeutics, 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (“Introgen”); and Pope Investments II LLC,
(“Pope Investments”). 
 WHEREAS, by the Exclusive License Agreement of July 19, 1999, as amended
August 8, 2000 and November 12, 2001 (collectively, the “Exclusive License Agreement”), Introgen is the exclusive licensee from Columbia of certain patents and technology relating to the use of the MDA-7 gene in treating disease;
and 
 WHEREAS, Columbia is successor in interest and assignee to all of the rights of Corixa Corporation and Chinook Corporation
under the Exclusive License Agreement; and 
 WHEREAS, Introgen desires to assign its entire interest and obligation as exclusive
licensee and any other interest and obligation under the Exclusive License Agreement to Pope Investments, which in turn will assign the Exclusive License Agreement rights to a new entity that is formed by Pope Investments in accordance with this
Agreement,(the “NEWCO”), and following such assignment, such NEWCO will succeed to all of Pope Investement interests and obligations under the Exclusive License Agreement; and 

WHEREAS, Columbia and Pope desire to amend the Exclusive License Agreement, as provided for herein, to extend the date for
accomplishing a certain milestone event pursuant to the Exclusive License Agreement; and 
 WHEREAS, Columbia and Pope Investment
desire to amend the Exclusive License Agreement, as provided for herein, regarding the transfer of technology to a Newco as further set forth below.; 

NOW, THEREFORE, it is agreed as follows: 

1. Extension of Date in Exclusive License Agreement. Paragraph 3.1(f) of the Exclusive License Agreement is amended to read as follows:

  

			
	 Event
	  	 Date of Accomplishment

		
	(f) Obtain FDA approval to market a vaccine or other therapeutic product in United States	  	On or before the fifth the anniversary of the New Effective Date

 2. Assignment to Pope Investments and Subsequent Sublicense to NEWCO. Introgen hereby
assigns its entire right, title and interest in and to the Exclusive License Agreement to Pope Investments. Columbia hereby consents to the foregoing assignment of the Exclusive License Agreement from Introgen to Pope Investments. Pope Investments
entire right, title and interest in and to the Exclusive License Agreement shall be subsequently sublicensed to NEWCO, as set forth below. Provided that the sublicense of the Exclusive License Agreement by Pope Investment to NEWCO is in accordance
with the terms of this Agreement, Columbia hereby consents to such sublicense. In addition, Pope Investment shall assign its rights, to the extent it is legally able to do so, to any and all intellectual property owned or controlled by Pope
Investment, as necessary or useful to support the development, manufacture and/or commercialization of either or both of the Licensed Technology and the Licensed Products, as such terms are defined in the Exclusive License Agreement (collectively
“Additional MDA-7 Rights”), to the NEWCO, as set forth below. The Exclusive License Agreement and the Additional MDA-7 Rights to be sublicensed and assigned, respectively, to NEWCO, shall be collectively referred to as the
“Technology.” 
  

	 	(a)	Creation of NEWCO. The parties agree to cooperate in the formation of a NEWCO in order to develop and commercialize the Technology in accordance with this Agreement, as follows: (1) Formation of NEWCO. Pope
Investments will form a new corporate entity to be the NEWCO hereunder, which formation shall be complete no later than sixty (60) days after Pope Investments have successfully concluded negotiations with Paul Fisher or another third party with
respect to development and commercialization of the Technology. The NEWCO’s initial capitalization will consist of founder’s shares held by Columbia equaling 15% of the outstanding common stock of the NEWCO. The remaining 85% of the
outstanding common stock of NEWCO shall be held by Pope Investments. The stock held by Columbia pursuant to this provision will be fully dilutable, founders-type shares and mirror the equity interest held by Pope Investments in the NEWCO at its
formation, and bear the same rights, preferences and privilege as the equity interest held by Pope Investments 

  

	 	(b)	Negotiations with Paul Fisher. Pope Investments will negotiate in good faith with Paul Fisher and his designees for the transfer of a portion of the 85% of the common stock in the Assignee, but Pope investments does not
make any guarantee that such equity interests will be granted. 

  

	 	(c)	NEWCO will enter into a mutually acceptable Development Plan with Columbia and Pope Investments in order to diligently develop and commercialize the Technology. 

3. Further Assurances. The parties agree (i) to furnish upon request to each other such further information, (ii) to execute
and deliver to each other such other documents, and (iii) to do such other acts and things, all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement and the actions required by this Agreement.

 4. Injunctive Relief. The parties recognize and acknowledge that irreparable damage might result to Columbia or Pope Investments
if this Agreement is breached by the other party. In the event of any such breach and in addition to all other remedies to which Columbia or Pope Investments may be entitled, Columbia or Pope Investments shall be entitled to pursue immediate and
injunctive relief from any court of competent jurisdiction in connection with such breach, notwithstanding the arbitration procedures provided for in the Exclusive License Agreement 

  
 2 

 5. Payment to Columbia. In consideration of the foregoing, Introgen shall pay in full to
Columbia, within ten (10) days from the date the Cure Amount is determined, monies due and owing to Columbia by Introgen under the Exclusive License Agreement (the ‘Cure Amount). The Cure Amount shall be determined though the good faith
negotiations of Dr. Robert Sobol and Shai Gilad with reference to the terms of the Exclusive License Agreement and shall be limited to only those expenses due and owing to Columbia pursuant to the Exclusive License Agreement. Such Cure Amount
paid to Columbia shall be non-refundable. In the event the parties cannot reach a mutually agreeable Cure Amount determination, then parties shall submit to a hearing in front of the Bankruptcy Court on November 16, 2009 at 1:30pm. 

6. Retained Right. Columbia has the right, in the event of failure by Pope Investments or Introgen to comply with the terms and
conditions of this Agreement, to terminate the Exclusive License Agreement in accordance with the notice and cure terms of the Exclusive License Agreement. 

7. Governing Law. This Agreement shall be governed by the laws of the State of New York, without regard to its principles of conflicts
of laws, notwithstanding Section 13.7 of the Exclusive License Agreement, The Parties further agree to subject themselves to the personal jurisdiction of the federal and state courts of the State of New York. 

8. Validity. This Modification and Assignment Agreement shall not be valid or enforceable without both Bankruptcy Court approval and
Columbia’s receipt of Cure Amount in verified funds. 
 9. No Other Changes. Except as herein amended, the Exclusive License
Agreement shall continue in full force and effect in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have caused this
Agreement to be executed by their duly authorized representatives as of the New Effective Date. 
  

			
	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	POPE INVESTMENTS II LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	INTROGEN THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 3 

 Schedule 3.2(e) Vivante Transferred Assets 

1 Vial: HEK293 Master Cell Bank 004374 (part number 08-00047) 

3 Vials: HEK293 Working Cell Bank WC007001 (part number 08-00050) 

 Schedule 6.6—Patent Costs 

 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:097U5D1	  	 Protamine Adenoviral Vector Complexes and Methods of Use
	  	5/09/07	  	11/746531	  		  	11/01/09: $130.00
						
	INRP:005USD2	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	6/11/02	  	10/170240	  	7033750	  	10/25/09: $1225.00
						
	INRP:005-AU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	80949/94	  	698437	  	10/28/09: $1301.00
						
	INRP:005-CA	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	2174556	  	2174556	  	10/28/09: $890.00
						
	INRP:005-CN	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	94194354.2	  	94194354.2	  	10/28/09: $1638.00
						
	INRP:005-CZ	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	PV1225-96	  	288790	  	10/28/09: $1421.00
						
	INRP:005-HU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	P9601084	  	222981	  	10/28/09: $1411.00
						
	INRP:005-PL	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	P314311	  	186151	  	10/28/09: $1243.00
						
	INRP:005-RU	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	96110223	  	2222600	  	10/28/09: $1120.00
						
	INRP:005-UA	  	 Recombinant P53 Adenovirus Methods and Compositions
	  	10/28/94	  	96041651	  	73265	  	10/28/09: $1302.00
						
	INGN:168WO	  	 P53 Biomarkers
	  	01/26/09	  	PCT/US2009/032029	  		  	Deadline to file Chapter 11 demand is 10/29/09
						
	INRP:008-AU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	23924/95	  	694216	  	10/24/09: $1300.00
						
	INRP:008-BR	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PI9507506.2	  		  	10/24/09: $1300.00
						
	INRP:008-BRD1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PI9510797.5	  		  	10/24/09: $1300.00
						
	INRP:008-CN	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95192776.0	  	95192776	  	10/24/09: $2000.00
						
	INRP:008-CZ	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	PV3121/96	  	295144	  	10/24/09: $2000.00
						
	INRP:008-EAT	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2300.00
						
	INRP:008-EAT1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	E383167	  	10/30/09: $2300.00
						
	INRP:008-EBE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.00	  	0760675	  	10/30/09: $1500.00
						
	INRP:008-EBE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1500.00

  
 1 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:008-ECH	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1300.00
						
	INRP:008-ECHL1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1300.00
						
	INRP:008-EDE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	69521994.4	  	10/30/09: $2700.00
						
	INRP:008-EES	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	2160707	  	10/30/09: $1600.00
						
	INRP:008-EES1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-EFR	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1700.00
						
	INRP:008-EGB	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1500.00
						
	INRP:008-EIE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	959171000.0	  	0760675	  	10/30/09: $1600.00
						
	INRP:008-EIE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-EIT	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2100.00
						
	INRP:008-EIT1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $2100.00
						
	INRP:008-ELU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1300.00
						
	INRP:008-ELU1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1300.00
						
	INRP:008-EMC	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1600.00
						
	INRP:008-EMC1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $1600.00
						
	INRP:008-ENL	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $2500.00
						
	INRP:008-ENL1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/30/09: $2500.00
						
	INRP:008-ESE	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	95917100.0	  	0760675	  	10/30/09: $1600.00

  
 2 

											
	 Docket No.
	  	 Title
	  	 Date
Filed
	  	 Application
No.
	  	Registration
No.	  	 Payment 
Due

						
	INRP:008-ESE1	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	01110982.4	  	1157702	  	10/24/09: $1600.00
						
	INRP:008-HU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	P9602937	  	221279	  	10/30/09: $2100.00
						
	INRP:008-PL	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	P-317105	  	185749	  	10/24/09: $1600.00
						
	INRP:008-RU	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	96122787	  	2146149	  	10/24/09: $2000.00
						
	INRP:008-NO	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/95	  	19964527	  	325560	  	10/30/09: $1700.00
						
	INRP:005E-	  	 Recombinant p53 Adenovirus Methods and Compositions
	  	10/28/94	  	94932099.8	  		  	11/3/09: $600.00
						
	AO-INRP:008	  	 Methods and Compositions Comprising DNA Damaging Agents and p53
	  	4/24/94	  	08/233002	  	5747469	  	11/5/09: $4110.00
						
	INRP:083US	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	09/575473	  		  	11/12/09: $1730.00
						
	INGN:147US	  	 Compositions and Methods Involving Gene Therapy and Proteasome Modulation
	  	9/16/08	  	11/672896	  		  	11/18/09: $130.00
						
	INRP:083EBE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1300.00
						
	INRP:083ECH	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EDE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	60030970.3	  	11/30/09: $1500.00
						
	INRP:083EES	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EFR	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00
						
	INRP:083EGB	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1300.00
						
	INRP:083EIT	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	36672BE/20 06	  	11/30/09: $2000.00
						
	INRP:083ESE	  	 Methods and Compositions for Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases
	  	5/24/00	  	00936279.9	  	1180016	  	11/30/09: $1400.00

  
 3EX-10.23

 Exhibit 10.23 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

PATENT AND TECHNOLOGY LICENSE AGREEMENT 

THIS AGREEMENT (“AGREEMENT”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM
(“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“MDA”), a component institution of the SYSTEM and INTRON THERAPEUTICS,
INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (“LICENSEE”). 

RECITALS 
 A. BOARD owns
certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED SUBJECT MATTER, which were developed at MDA, a component institution of the SYSTEM. 

B. BOARD desires to have the LICENSED SUBJECT MATTER developed and used for the benefit of LICENSEE, the inventor, BOARD, and the public as
outlined in the Intellectual Property Policy promulgated by the BOARD. 
 C. The LICENSED SUBJECT MATTER was the subject of an OPTION
AGREEMENT between MDA and the Texas Biomedical Development Partners (“TBDP”), dated December 15, 1992, a copy of which is attached hereto as Exhibit 1 for approval by BOARD, granting TBDP the option to negotiate a license from BOARD
to the LICENSED SUBJECT MATTER in consideration for an option fee and commitment of research support. 
 D. TBDP exercised its option under
the OPTION AGREEMENT in a timely manner by virtue of the letter dated June 17, 1993, a copy of which is attached hereto as Exhibit 2 for approval by BOARD, and further assigned TBDP’s right and obligations under the OPTION AGREEMENT
(Exhibit 1) to LICENSEE, thereby granting permission to BOARD to execute this LICENSE AGREEMENT with LICENSEE. 
 E. The LICENSED SUBJECT
MATTER was also the subject of SPONSORED RESEARCH AGREEMENTS between MDA and the TBDP, entitled “Development of Therapeutic Treatment and Prevention of Lung Cancer” (SR93-04) and “Clinical Protocol for Modification of Oncogene and
Tumor Suppressor Gene Expression in Nori-Small Cell Lung Cancer (CS93-27), respectively, and a copy of each is attached hereto as Exhibits 3 and 4 (the “RESEARCH AGREEMENTS”). 

F. The RESEARCH AGREEMENTS have been assigned by TBDP to LICENSEE by virtue of a letter dated November 26, 1993, a copy of which is
attached hereto as Exhibit 5 for approval by BOARD. 

 G. LICENSEE is a company which was formed to develop and commercially exploit the inventions of
LICENSED SUBJECT MATTER, and LICENSEE, therefore, wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER. 
 NOW,
THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties hereto agree as follows: 
 I. EFFECTIVE
DATE 
 1.1 This AGREEMENT shall be effective as of July 20, 1994 (“EFFECTIVE DATE”), subject to approval by BOARD. 

II. DEFINITIONS 
 As used
in this AGREEMENT, the following terms shall have the meanings indicated: 
 2.1 LICENSED FIELD shall mean all fields of use of the LICENSED
SUBJECT MATTER. 
 2.2 LICENSED SUBJECT MATTER shall mean inventions and discoveries covered by PATENT RIGHTS or TECHNOLOGY RIGHTS within
LICENSED FIELD. 
 2.3 PATENT RIGHTS shall mean any and all rights of BOARD in and to: 

(a) the patents and patent applications described in Schedule A hereto (the “Existing Patent Rights”) and all patents anywhere in the
world issuing thereon; 
 (b) any patent or patent application of any kind anywhere in the world that claims or discloses any invention that
is claimed in any of the Existing Patent Rights, or that takes priority from an application within the Existing Patent Rights or derives from an application from which any of the Existing Patent Rights derived; 

(c) all divisions, continuations, continuations-in-part, patents of addition, patents, substitutions, registrations, reissues, reexaminations
or extensions of any kind with respect to any of the applications and patents described in (a) or (b) above. From time to time during the term of this AGREEMENT, upon request by either party, LICENSEE and BOARD shall promptly update
Schedule A hereto to include all patent applications and patents that are then within the PATENT RIGHTS. 
 2.4 TECHNOLOGY RIGHTS shall mean
BOARD’s rights in any technical information, know-how, process, procedure, composition, biological materials, device, method, formula, protocol, technique, software, design, drawing or data relating to LICENSED FIELD and made or developed by
Dr. Jack A. Roth or others working in his lab or under his supervision or direction, whether or not covered by PATENT RIGHTS, which is reasonably necessary for practicing an invention at any time covered by PATENT RIGHTS. 

  
 2 

 2.5 LICENSED PRODUCT shall mean any product, component or material the manufacture, use or sale
of which would infringe a VALID CLAIM. 
 2.6 LICENSED TERRITORY shall mean the entire world. 

2.7 SALE or sold shall mean the transfer or disposition of a LICENSED PRODUCT for value to a party other than LICENSEE or an AFFILIATE, which
transfer or disposition would, but for the rights and license granted hereunder, infringe a VALID CLAIM in the country for which such LICENSED PRODUCT is transferred or disposed. 

2.8 NET SALES shall mean the gross revenues received by LICENSEE, its AFFILIATES or SUBLICENSEES, from the SALE of LICENSED PRODUCTS less
sales and/or use taxes actually paid, import and/or export duties actually paid, outbound transportation prepaid or allowed, and amounts allowed or credited due to returns (not to exceed the original billing or invoice amount). 

2.9 AFFILIATE shall mean any business entity more than 50% owned by LICENSEE, or any business entity that is more than 50% owned by a business
entity that owns more than 50% of LICENSEE. 
 2.10 VALID CLAIM shall mean either (a) a claim of an issued and unexpired patent
included within the PATENT RIGHTS, which has not been held unenforceable, unpatentable or invalid by a court or other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise, or (b) a pending claim in a patent application within the PATENT RIGHTS, provided that if such pending claim has not issued as a claim or an issued patent within the PATENT RIGHTS within three (3) years after the
filing date from which such patent application takes priority, such pending claim shall not be a VALID CLAIM for purposes of this AGREEMENT unless and until, subsequent to such three (3) year period, such pending claim is issued as a claim of
an issued and unexpired patent included within the PATENT RIGHTS as set forth in (a) above. In the event that a claim of an issued and unexpired patent within the PATENT RIGHTS is held by a court or other governmental agency of competent
jurisdiction to be unenforceable, unpatentable or invalid, and such holding is reversed on appeal by a higher court or agency of competent jurisdiction, such claim shall be reinstated thereafter as a VALID CLAIM hereunder. 

2.11 SUBLICENSEE shall mean any third party to whom LICENSEE has granted a sublicense under the PATENT RIGHTS to make and sell LICENSED
PRODUCTS, with respect to LICENSED PRODUCTS made and sold by such SUBLICENSEE. As used herein, “SUBLICENSEE” shall also mean a third party to whom LICENSEE has granted the exclusive right to distribute LICENSED PRODUCTS supplied by
LICENSEE, provided that such third party is responsible for all marketing and promotion of the subject LICENSED PRODUCTS within its exclusive territory. 

  
 3 

 III. WARRANTY: SUPERIOR-RIGHTS 

3.1 Except for the rights, if any, of the Government of the United States as set forth hereinbelow, BOARD represents and warrants its belief
that it is the owner of the entire right, title, and interest in and to LICENSED SUBJECT MATTER, and that it has the sole right to grant licenses thereunder, and that it has not granted licenses thereunder to any other entity that would restrict
rights granted hereunder except as stated herein. In addition, BOARD represents and warrants that it owns and will own all right, title and interest in and to the patent applications listed in Exhibit A as of the Effective Date, and all patents that
will issue thereon; and that the patents listed on Exhibit A comprise all patents and applications owned by BOARD or MDA that claim inventions of any of the inventors listed therein which pertain to the p53 gene or K-ras or gene therapy. 

3.2 LICENSEE understands that the LICENSED SUBJECT MATTER may have been developed under a funding agreement with the Government of the United
States of America and, if so, that the Government may have certain rights relative thereto. This AGREEMENT is explicitly made subject to the Government’s rights under any such agreement and any applicable law or regulation, including P.L.
96-517 as amended by P.L. 98-620. To the extent that there is a conflict between any such agreement, applicable law or regulation and this Agreement, the terms of such Government agreement, applicable law, or regulation shall prevail. 

3.3 BOARD, by this AGREEMENT, makes no representation as to the patentability, validity, and/or breadth of the inventions contained in the
PATENT RIGHTS. BOARD, by this AGREEMENT, makes no representation as to whether there are any patents now held, or which will be held, by others or by BOARD in the LICENSED FIELD, nor does BOARD make any representation that the inventions contained
in PATENT RIGHTS do not infringe any other patents now held or that will be held by others or by BOARD. 
 IV. LICENSE 

4.1 BOARD hereby grants to LICENSEE a royalty-bearing, exclusive license under the LICENSED SUBJECT MATTER to manufacture, have manufactured,
use and/or sell LICENSED PRODUCTS, to practice any method, process or procedure and to otherwise exploit the LICENSED SUBJECT MATTER, within LICENSED TERRITORY for use within LICENSED FIELD. Subject to Paragraph 5.8 herein, such license shall extend
to BOARD’s undivided interest in any LICENSED SUBJECT MATTER developed during the term of this AGREEMENT and jointly owned by BOARD and LICENSEE. This grant shall be subject to Paragraph 3.2, hereinabove, the payment by LICENSEE to BOARD of all
consideration as provided in this AGREEMENT, including the timely payment of all amounts due during the term of this Agreement under any sponsored research agreement covering the Licensed Subject Matter between MDA and LICENSEE (including but not
limited to the RESEARCH AGREEMENTS, reimbursement of MDA’s patent expenses as set forth in Paragraph 5.7 below, and shall be further subject to rights retained by BOARD and MDA to: 

(a) Publish the general scientific findings from research related to LICENSED SUBJECT MATTER; and 

  
 4 

 (b) Use any information contained in LICENSED SUBJECT MATTER for research, teaching, patient
care, and other educationally-related purposes. 
 Notwithstanding the foregoing, the license granted in this Section 4.1 under
TECHNOLOGY RIGHTS not covered by any PATENT RIGHTS shall be non-exclusive for all applications that do not pertain in any way to the p53 gene, the k-ras gene, or mutations thereof, the genetic or functional inhibition or promotion thereof; the
translation or transcription pathways of such genes or mutations thereof, or any protein or molecule expressed by such genes or mutations thereof. 

4.2 LICENSEE shall have the right to extend the license granted herein to any AFFILIATE provided that such AFFILIATE consents in writing, with
copy to BOARD, to be bound by this AGREEMENT to the same extent as LICENSEE. 
 4.3 The license granted under Paragraph 4.1 above shall
include the rights to grant and authorize sublicenses within the scope of the right and license granted to LICENSEE. LICENSEE shall monitor the operations of its SUBLICENSEES in connection with the obligations of LICENSEE pursuant to this AGREEMENT,
and shall use reasonable efforts to ensure that such SUBLICENSEES comply fully with such obligations. LICENSEE shall promptly inform BOARD of the name and address of each such SUBLICENSEE, and subject to any obligations of confidentiality to the
SUBLICENSEE, shall provide MDA a copy of the sublicense agreement. 
 V. PAYMENTS AND REPORTS 

5.1 In consideration of rights granted by BOARD to LICENSEE under this AGREEMENT, LICENSEE agrees to pay MDA the following: 

(a) [***] ([***]%) of NET SALES attributed to SALES of LICENSED PRODUCTS by LICENSEE, AFFILIATES and SUBLICENSEES; and 

(b) For any advance payment received by LICENSEE from a third party pursuant to a sublicense, marketing, distribution, or franchise agreement,
other than amounts paid to LICENSEE in reimbursement of development or other costs, as provided for in Article 4.3 hereof and which is creditable against future royalties to be received by LICENSEE: one and one half percent (1.5%) of said
advance payment. 
 (c) LICENSEE will not be obligated to pay MDA any portion of any advanced payment received by LICENSEE from a third
party that is not creditable against future running royalties to be received by LICENSEE. 
 (d) If LICENSEE desires to fund sponsored
research, and particularly where LICENSEE receives R&D money in lieu of or in addition to royalty revenues pursuant to a sublicense, LICENSEE shall give good faith consideration to funding such proposals at MDA. 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 5 

 5.2 In the event that more than one patent within the PATENT RIGHTS is applicable to any LICENSED
PRODUCT subject to royalties under this Article V, then only one royalty shall be paid to MDA in respect of such quantity of the LICENSED PRODUCTS and in any event no more than one royalty will be payable hereunder with respect to any particular
LICENSED PRODUCT unit. In addition: 
 (a) No royalty shall be payable under Paragraph 5.1 above with respect to the SALE of LICENSED
PRODUCTS between or among LICENSEE, AFFILIATES and SUBLICENSEES, provided that such LICENSED PRODUCTS are to be resold to unrelated third parties, or with respect to any fees or other payments paid between or among LICENSEE and AFFILIATES; nor shall
a royalty be payable under Paragraph 5.1 with respect to SALES of LICENSED PRODUCTS for use in clinical trials or as samples. 
 (b) In the
event that a LICENSED PRODUCT is sold in combination as a single product, or in a kit, with another product or component and no royalty would be due hereunder on the sale of such other product or component alone, then NET SALES from such combination
sales for purposes of calculating the amounts due under this Article V shall be as reasonably allocated by LICENSEE between such LICENSED PRODUCT and such other product or components, based upon their relative importance and proprietary protection
as commercially reasonable. 
 5.3 During the Term of this Agreement and for one (1) year thereafter, LICENSEE shall keep complete and
accurate records if its SALES and NET SALES of LICENSED PRODUCTS and other income subject to royalties hereunder and all revenues received from all SUBLICENSEES to enable the royalties payable hereunder to be determined. LICENSEE shall permit BOARD
or its representatives, at BOARD’s expense, to periodically examine its books, ledgers, and records during regular business hours for the purpose of and to the extent that the amounts due to BOARD are determined to have been underpaid LICENSEE
shall pay the cost of such examination, and accrued interest at the highest allowable rate. 
 5.4 Within thirty (30) days after
March 31, June 30, September 30, and December 31, LICENSEE shall deliver to BOARD and MDA a true and accurate report, giving such particulars of the business conducted, if any, by LICENSEE, including all revenues
received from all SUBLICENSEES, during the preceding three (3) calendar months under this AGREEMENT as are pertinent to an account for payments hereunder. Such report shall include at least (a) the quantities of LICENSED SUBJECT MATTER
that it has produced; (b) the total SALES, (c) the calculation of royalties thereon; and (d) the total royalties so computed and due BOARD. Simultaneously with the delivery of each such report, LICENSEE shall pay to BOARD the amount,
if any, due for the period of such report. If no payments are due, it shall be so reported. 
 5.5 Upon the request of BOARD or MDA but not
more often than once per calendar year, LICENSEE shall deliver to BOARD and MDA a written report as to LICENSEE’s efforts and accomplishments during the preceding year in commercializing LICENSED SUBJECT MATTER in various parts of the LICENSED
TERRITORY and its commercialization plans for the upcoming year. 

  
 6 

 5.6 All amounts payable hereunder by LICENSEE shall be payable in United States funds. Checks
shall be made payable to The University of Texas M.D. Anderson Cancer Center. Any withholding or other tax that LICENSEE, an AFFILIATE, or a SUBLICENSEE are required by law to withhold shall be deducted from royalties owing to MDA hereunder and
promptly paid to the taxing authority. If royalties paid to LICENSEE or an AFFILIATE by a SUBLICENSEE on NET SALES of LICENSED PRODUCTS are reduced for withholding or similar taxes, LICENSEE may deduct a portion of such tax from the royalties
payable to UNIVERSITY with respect to such Net Sales; the portion to be so deducted shall equal the amount of the tax multiplied by the fraction B/A, where “A” equals the gross royalty payable to LICENSEE on such Net Sales prior to the
withholding or similar tax, and “B” equals the gross royalty payable to UNIVERSITY on such Net Sales prior to the reduction under this Section 5.6. In regard to any tax so deducted, LICENSEE shall furnish UNIVERSITY with proper
evidence of the taxes paid. In the event that LICENSEE realizes a reduction in its U.S. tax liability by reason of a foreign tax credit with respect to withholding taxes so deducted from royalties payable to MDA hereunder, LICENSEE shall pay to MDA
the amount of such reduction in its U.S. tax liability. 
 5.7 LICENSEE shall reimburse MDA for all of its out-of-pocket expenses thus far
incurred in filing, prosecuting, enforcing and maintaining PATENT RIGHTS exclusively licensed hereunder and which were not already reimbursed pursuant to the Option Agreement in Exhibit I hereto, and shall pay all such future expenses so long as and
in such countries as its license remains exclusive. In the event that LICENSEE notifies MDA that it does not wish to reimburse further expenses of prosecuting or maintaining any application or patent within the PATENT RIGHTS in any country, LICENSEE
shall not be responsible for any such expenses with respect to such application or patent after MDA’s receipt of such notice, and LICENSEE’s license under Paragraph 4.1 above shall become nonexclusive with respect to such application (and
any patent issuing thereon) or patent in such country. MDA will invoice LICENSEE on a quarterly basis beginning October 1, 1994,, with such invoices being due and payable within thirty (30) days thereafter. 

5.8 No payments due or royalty rates under this AGREEMENT shall be reduced as the result of co-ownership of LICENSED SUBJECT MATTER by BOARD
and LICENSEE. 
 5.9 It is understood that royalties shall be due under 5.1(a) above only on SALES of LICENSED PRODUCTS, the SALE of which
would, but for the license granted herein, infringe a VALID CLAIM in the country for which such LICENSED PRODUCT is SOLD. However, if the SALE of a LICENSED PRODUCT would infringe a VALID CLAIM in the United States, Japan and at least four
(4) Major Countries in Europe, LICENSEE shall pay royalties hereunder on all sales of such LICENSED PRODUCT in any country, regardless of whether the sale of such product in such country would infringe a VALID CLAIM. As used herein, “Major
Countries” shall mean the United Kingdom, France, Germany, Spain, Italy, Sweden and Switzerland. 
 5.10 Effective upon written notice
to MDA, LICENSEE may convert the license granted to LICENSEE under Paragraph 4.1 with respect to any patent or application within the PATENT RIGHTS to a non-exclusive license. Following such notice, the amounts to be paid to MDA under Paragraph 5.1
above with respect to any VALID CLAIMS within such patent or application, after any other adjustment under this AGREEMENT, shall be reduced by one-half. 

  
 7 

 VI. PATENTS AND INVENTIONS 

6.1 If after consultation with LICENSEE it is agreed by BOARD and LICENSEE that a new patent application should be filed for LICENSED SUBJECT
MATTER, BOARD will prepare and file appropriate patent applications, and LICENSEE will pay the cost of searching, preparing, filing, prosecuting and maintaining same, subject to Paragraph 5.7 above. BOARD shall provide LICENSEE with a copy of the
new patent application for which LICENSEE has paid the cost of filing, as well as copies of any documents received or filed during prosecution thereof. BOARD shall consult with LICENSEE in a timely manner concerning (i) scope and content of all
patent applications within the PATENT RIGHTS prior to filing such patent applications, and (ii) content of and proposed responses to official actions of the United States Patent and Trademark Office and foreign patent offices during prosecution
of any patent applications within the PATENT RIGHTS. For purposes of this Paragraph 6.1, “timely” shall mean sufficiently in advance of any decision by BOARD or any deadline imposed upon written response by BOARD so as to allow LICENSEE to
meaningfully review such decision or written response and also provide comments to BOARD in advance of such decision or deadline to allow comments of LICENSEE respect to the PATENT RIGHTS to be considered and incorporated into BOARD’s decision
or written response. 
 6.2 With respect to the filing of any patent application within the PATENT RIGHTS, or the prosecution of any patent
application within the PATENT RIGHTS, or the maintenance of any patent within the PATENT RIGHTS, if BOARD elects not to file for or continue prosecution of any such patent application or maintain any such patent, BOARD shall promptly notify LICENSEE
in writing sufficiently in advance of any deadline to enable LICENSEE to file for or continue prosecution of such patent application and/or maintain such patent, and in such event LICENSEE (or its designee) may at its discretion pursue such filing,
prosecution and/or maintenance of its own expense in BOARD’s name. 
 VII. INFRINGEMENT AND DEFENSE 

7.1 LICENSEE agrees, itself or through its designee, to use reasonable efforts generally to enforce the PATENT RIGHTS with respect to substantial continuing
infringements of the PATENT RIGHTS within the LICENSED FIELD, by initiating legal action, sublicensing the infringing activities or otherwise. It is understood, however, that such obligation shall not be deemed to require LICENSEE to take such
actions with respect to each such infringement, and LICENSEE may take into account reasonable strategic and other considerations in determining which infringers to take action against, as well as when and whether to do so. If LICENSEE or its
designee commences an action to enforce the PATENT RIGHTS, LICENSEE shall have the right during the pendency of the action to withhold up to, but not more than, [***] ([***]%) of the royalties payable to BOARD hereunder based on the SALE of the
LICENSED PRODUCTS covered by the patent within the PATENT RIGHTS in dispute to offset LICENSEE’s and its SUBLICENSEE’s out-of-pocket legal expenses incurred in connection with such action or proceeding. Any portion of such withheld 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 8 

 
royalties that is not so applied, shall be promptly paid to BOARD after such action or proceeding is resolved or abandoned. Any amounts recovered from third parties by LICENSEE or a SUBLICENSEE
with respect to the PATENT RIGHTS in such action or proceeding shall be applied first to reimburse any outstanding legal expenses of the action or proceeding incurred by LICENSEE or such SUBLICENSEE, and then to reimburse BOARD for any royalties or
fees withheld under this Paragraph 7.1 with respect to such action or proceeding. Any amounts remaining shall be included in NET SALES of LICENSEE or such SUBLICENSEE (as the case may be) for purposes of calculating royalties owed pursuant to
Paragraph 5.1(a). 
 7.2 In the event that LICENSEE does not fulfill its obligations under Paragraph 7.1 above, MDA shall have the right to
enforce the PATENT RIGHTS relating to infringement by such a substantial infringer on behalf of MDA and LICENSEE; and in such event MDA shall have the right to grant a nonexclusive license, under the PATENT RIGHTS that are the subject of such
action, to the claimed infringer to make, use and sell the infringing products in the countries where such products are being sold at the time the action is commenced. Any amounts recovered or received from third parties by MDA with respect to the
PATENT RIGHTS in such action, proceeding or license shall be retained by MDA. 
 7.3 In the event that LICENSEE, an AFFILIATE or SUBLICENSEE
receives a claim from a third party alleging an infringement of intellectual property rights of a third party based upon the manufacture, sale or use of a LICENSED PRODUCT, LICENSEE shall have the right to withhold [***] ([***]%) [***] payable to
BOA.RD hereunder arid apply such amounts against LICENSEE’s and such AFFILIATES’ or SUBLICENSEES’ out-of-pocket expenses incurred in defending such claim. Any and all withheld amounts that are not so used shall promptly be reimbursed
to BOARD after the resolution of such claim. 
 7.4 In any suit or dispute involving the enforcement or defense of PATENT RIGHTS, the
parties shall cooperate fully, including without limitation, subject to the statutory authority of the Attorney General of the State of Texas as applicable to BOARD and MDA, by joining as a party plaintiff and executing such documents as the party
prosecuting such suit, action or other proceeding may reasonably request, all at such requesting party’s expense. Upon the request and at the expense of the party bringing suit, the other party shall make available to the party bringing suit at
reasonable times and under appropriate conditions all relevant personnel, records, papers, information, samples, specimens, and the like which are in its possession. 

VIII. PATENT MARKING 
 8.1
LICENSEE agrees that all packaging containing individual LICENSED PRODUCT(S), and documentation therefor, sold by LICENSEE, AFFILIATES and SUBLICENSEES of LICENSEE will be marked permanently and legibly with_ the number of the applicable patent(s)
licensed hereunder in accordance with each country’s patent laws, including Title 35, United States Code. 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 9 

 IX. INDEMNIFICATION 

9.1 LICENSEE shall hold harmless and indemnify BOARD, SYSTEM, MDA, its Regents, officers, employees, students, and agents from and against any
claims, demand, or causes of action whatsoever, including without limitation those arising on account of any injury or death of persons or damage to property, caused by, or arising out of, or resulting from, the exercise or practice of the license
granted hereunder by LICENSEE or its officers, employees, agents or representatives. 
 9.2 BOARD shall, to the extent authorized under the
Constitution and the laws of the State of Texas, hold LICENSEE harmless from liability resulting from the negligent acts or omissions of BOARD or MDA, their agents or employees pertaining to the activities to be carried out pursuant to the
obligations of this AGREEMENT; provided, however, that BOARD shall not hold LICENSEE harmless from claims arising out of the negligence of LICENSEE, its officers, agents or any person or entity not subject to BOARD’s or MDA’s supervision
or control. 
 X. USE OF BOARD AND COMPONENTS NAME 

10.1(A) In accordance with BOARD policy, LICENSEE shall not use the name of BOARD, SYSTEM or BOARD, except as described in 10.1 (B), below,

 (B)(i) LICENSEE may use the name of MDA, BOARD, or SYSTEM only when indicating, as a factual matter, that MDA, BOARD, or SYSTEM is a
licensor of LICENSEE under this AGREEMENT and only in connection with either or both of the following: 
 (a) communications associated with
LICENSEE’s financing activities; and 
 (b) communications (other than promotions and advertisements) directed to describing or
responding to inquiries concerning the business, technology, products, services and associated activities of LICENSEE. 
 (c) in all such
communications, LICENSEE shall limit such use, in substance, to stating that a LICENSED PRODUCT or other LICENSED SUBJECT MATTER was invented by the inventor thereof as an employee of MDA and/or that MDA and/or BOARD is the licensor thereof. In no
event shall LICENSEE use the name of MDA, SYSTEM or BOARD in product advertising or on product packaging or labels affixed to any products. Communications in accordance with this Section 10.1(B) shall not be deemed a breach of Section 6 of
either of the RESEARCH AGREEMENTS. 
 (ii) LICENSEE may otherwise use the name of MDA, BOARD, or SYSTEM when and as required by applicable
law, rules and regulations, or upon written consent of the party the use of whose name is requested. 

  
 10 

 XI. CONFIDENTIAL INFORMATION 

11.1 BOARD and LICENSEE each agree that all information contained in documents marked “confidential” which are forwarded to one by
the other shall be received in strict confidence, used only for the purposes of this AGREEMENT, and not disclosed by the recipient party (except as required by law or court order), its agent or employees without the prior written consent of the
other party, unless such information (a) was in the public domain at the time of disclosure, (b) later became part of the public domain through no act or omission of the recipient party, its employees, agents, successors or assigns,
(c) was lawfully disclosed to the recipient party by a third party having the right to disclose it, (d) was already known by the recipient party at the time of disclosure, (e) was independently developed or (f) is required to be
submitted to a government agency or as otherwise required by law. Notwithstanding the foregoing or any provision of the RESEARCH AGREEMENTS, LICENSEE may disclose any LICENSED SUBJECT MATTER comprising confidential information of BOARD to third
parties pursuant to a reasonable confidentiality agreement, and otherwise as is reasonably necessary to exploit the LICENSED SUBJECT MATTER as contemplated in this AGREEMENT. 

11.2 Each party’s obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other
party’s confidential information as it uses to protect its own confidential information. This obligation shall exist while this AGREEMENT is in force and for a period of three (3) years thereafter. 

XII. ASSIGNMENT 
 12.1
This AGREEMENT may not be assigned by LICENSEE without the prior written consent of BOARD; provided that, at any time after eighteen (18) months after the Effective Date, LICENSEE may assign this AGREEMENT without such consent to a party that
acquires substantially all of the business or assets of LICENSEE to which this AGREEMENT pertains, so long as LICENSEE notifies BOARD and the assignee agrees in writing to be bound by the terms of this AGREEMENT. 

XIII. DUE DILIGENCE 
 13.1
BOARD shall have a right after five (5) years from the EFFECTIVE DATE to terminate the exclusivity of the license granted by BOARD to LICENSEE pursuant to Paragraph 4.1 in any national political jurisdiction within the LICENSED TERRITORY at any
time upon written notice to LICENSEE if LICENSEE fails to provide written evidence, within one hundred eighty (180) days after receiving written notice from BOARD of BOARD’s intention to terminate such exclusivity, that LICENSEE is using
commercially reasonable efforts to commercialize a LICENSED PRODUCT in such jurisdiction; provided that termination of such exclusivity shall not occur unless and until a court of competent jurisdiction has determined in a suit filed by LICENSEE
within such one hundred eighty (180) day period, that LICENSEE has not satisfied LICENSEE’s obligations hereunder, and LICENSEE fails to meets its obligations hereunder within six (6) months after such determination. Evidence provided
by LICENSEE in writing that LICENSEE has an ongoing and active research, development, manufacturing, marketing or sublicensing program (as appropriate), directed toward the development, production or sale of one or more LICENSED

  
 11 

 
PRODUCTS within either the United States, Japan or Europe shall be deemed satisfactory evidence that LICENSEE has commercialized or is using commercially reasonable efforts to commercialize a
LICENSED PRODUCT and to meet the market demand therefor worldwide for all purposes of this Article XIII. 
 XIV. TERM, TERMINATION, AND
DEFAULT 
 14.1 The term of this AGREEMENT shall extend from the Effective Date set forth hereinabove to the full end of the term or
terms for which PATENT RIGHTS have not expired and if only TECHNOLOGY RIGHTS are licensed and no PATENT RIGHTS are applicable, for a term of fifteen (15) years. Notwithstanding the above, upon the expiration, but not an earlier termination of
this AGREEMENT, LICENSEE shall have a non-exclusive, fully paid-up right and license under the LICENSED SUBJECT MATTER to use and otherwise exploit the TECHNOLOGY RIGHTS. 

14.2 This AGREEMENT will earlier terminate: 

(a) upon the expiration of thirty (30) days written notice from BOARD if LICENSEE shall become bankrupt and/or if the business of LICENSEE
shall be placed in hand of a receiver, assignee, or trustee, whether by voluntary act of LICENSEE or otherwise; 
 (b) (i) upon thirty
(30) days written notice from BOARD if LICENSEE shall breach or default on the payment obligations of Article V, or use of name obligations of Article X; or (ii) upon ninety (90) days written notice if LICENSEE shall breach or default
any other obligation under this AGREEMENT; provided, however, LICENSEE may avoid such termination if before the end of the applicable period LICENSEE notifies BOARD that such breach has been cured and states the manner of such cure. However, if
LICENSEE disputes such breach in writing within such thirty (30) or ninety (90) day period, BOARD shall not have the right to terminate this AGREEMENT unless and until a court of competent jurisdiction has determined, in a suit filed by
LICENSEE within such thirty (30) or ninety (90) day period, that this AGREEMENT was materially breached, and LICENSEE fails to cure such breach within thirty (30) or ninety (90) days (respectively) after such determination;
provided that the foregoing shall not suspend any obligation of LICENSEE to pay to BOARD any undisputed amount owed by LICENSEE to BOARD or MDA under this AGREEMENT, during the pendency of any determination of breach. 

(c) In its entirety or as to any particular patent application or patent within the PATENT RIGHTS, upon LICENSEE’s sixty (60) days
prior written notice to BOARD. From adn after the effective date of a termination under this Paragraph 15.2(c) with respect to a particular patent application or patent, such patent application and patent in the particular country shall cease to be
within the PATENT RIGHTS for all purposes of this AGREEMENT. Upon a termination of this AGREEMENT in its entirety under this Paragraph 15.2(c), all rights and obligations of LICENSEE and BOARD shall terminate, except as provided below. 

14.3 Upon termination of this AGREEMENT for any cause, nothing herein shall be construed to release either party of any obligation matured
prior to the effective date of such termination. LICENSEE may, after the effective date of such termination, sell all LICENSED PRODUCT and parts therefore that it may have on hand at the date of termination, provided that it pays earned royalty
thereon as provided in this AGREEMENT. 

  
 12 

 14.4 Articles IX, X, and XI, shall survive the expiration and any termination of this AGREEMENT.
In addition, upon termination of this AGREEMENT, any and all existing sublicenses shall survive; provided that such SUBLICENSEES promptly agree in writing to be bound by the applicable terms of this AGREEMENT. Except as otherwise provided in this
Article XV, all rights and obligations of the parties under this AGREEMENT shall terminate upon the expiration or termination of this AGREEMENT. 

XV. GENERAL 
 15.1 This
AGREEMENT constitutes the entire and only AGREEMENT between the parties for LICENSED SUBJECT MATTER and all other prior negotiations, representations, agreements (including that certain PATENT AND TECHNOLOGY LICENSE AGREEMENT between the parties
hereto executed on April 21, 1994 but not approved by BOARD) and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by means of a written document signed by the duly authorized
representatives of the parties. 
 15.2 Any notice required by this AGREEMENT shall be given by prepaid, first class, certified mail, return
receipt requested, and addressed in the case of BOARD to: 
  

			
		 	BOARD OF REGENTS
		 	The University of Texas System
		 	201 West Seventh Street
		 	Austin, Texas 78701
		 	ATTENTION: Office of General Counsel
		
	 with a copy to:
	 	The University of Texas
		 	M.D. Anderson Cancer Center
		 	Office of Technology Development
		 	1020 Holcombe Boulevard, Suite 1405
		 	Houston, Texas 77030
		 	ATTENTION: William J. Doty
		
	 or in the case of LICENSEE to:
	 	Intron Therapeutics, Inc.
		 	301 Congress, Suite 2025
		 	Austin, Texas 78701
		 	ATTENTION: Mr. David Nance
		
	 with a copy to:
	 	Kenneth A. Clark, Esq.
		 	Wilson, Sonsini, Goodrich & Rosati
		 	650 Page Mill Road
		 	Palo Alto, California 94304

 or such other address as may be given from time to time under the terms of this notice provision. 

  
 13 

 15.3 LICENSEE shall comply with all applicable federal, state and local laws and regulations in
connection with its activities pursuant to this AGREEMENT. 
 15.4 This AGREEMENT shall be construed and enforced in accordance with the
laws of the United States of America and of the State of Texas. 
 15.5 Failure of BOARD to enforce a right under this AGREEMENT shall not
act as a waiver of that right or the ability to later assert that right relative to the particular situation involved. 
 15.6 Headings
included herein are for convenience only and shall not be used to construe this AGREEMENT. 
 15.7 If any provision of this AGREEMENT shall
be found by a court to be void, invalid or unenforceable, the same shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of this AGREEMENT. 

  
 14 

 IN WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute
this AGREEMENT. 
  

									
	 THE UNIVERSITY OF TEXAS
 M.D.
ANDERSON CANCER CENTER
	  		 	 BOARD OF REGENTS OF THE
 UNIVERSITY
OF TEXAS SYSTEM

					
	 By
	 	 /s/ David J. Bachrach
	  		 	By	 	 /s/ Thomas G. Ricks

		 	David J. Bachrach	  		 		 	Thomas G. Ricks
		 	Executive Vice President	  		 		 	Vice Chancellor for
		 	For Administration and Finance	  		 		 	Asset Management
			
	APPROVED AS TO CONTENT	  		 	APPROVED AS TO FORM
					
	 By:
	 	 /s/ William J. Doty
	  		 	By:	 	 /s/ Dudley R. Doble

		 	William J. Doty	  		 		 	Dudley R. Doble, Jr.
		 	Director, Technology Development	  		 		 	Manager, Intellectual Property
				
	INTRON THERAPEUTICS, INC.	  		 		 	
					
	 By
	 	 /s/ David G. Nance
	  		 		 	
		 	David G. Nance	  		 		 	
		 	President	  		 		 	

 ATTACHMENT A 

Patent and technology rights for U.S. and Foreign Patent Application entitled: 
  

	 	•	 	“Methods and Compositions for the Selective Inhibition of Gene Expression” Inventors: Jack A. Roth, M.D., et. al. 

  

	 	•	 	Australia Serial No. 15704/92, filed March 6, 1992; Canada Serial No. 2108144, filed March 6, 1992; European Serial No. 92908663-5, filed March, 6, 1992, (MDA Ref. UTSC:171); and

  

	 	•	 	“Methods and Compositions for Retroviral Vector Mediated Transduction” Continuation-in-part U.S. Serial No. 960513, filed October 13, 1992, (MDA Ref. UTSC:295); and 

 

	 	•	 	“Methods and Compositions for the Selective Inhibition of Gene Expression” Continuation-in-part U.S. Serial No. 987235, filed December 7, 1992, (MDA Ref. UTSC:328); and 

 

	 	•	 	“Recombinant p53 Adenovirus Methods and Compositions” Continuation-in-part U.S. Serial No. 145826, filed October 29, 1993, (MDA Ref. UTSC:350); and 

 

	 	•	 	“An Adenovirus Supervector System” Continuation-in-part patent has not been filed yet (MDA Ref. UTSC:382); and 

  

	 	•	 	“Recombinant p53 Adenovirus Methods and Compositions” U.S. Serial No. 224232, filed April 7, 1994, (MDA Ref. UTSC:402); and 

 

	 	•	 	“Methods and Compositions Comprising DNA Damaging Agents and p53” Continuation-in-part patent has not been filed yet (MDA Ref. UTSC:403); and 

 

	 	•	 	“Use of Lectins for the Delivery and Translocation of Genetic Material Across Cell Membranes” patent has not filed yet (MDA Ref. UTSC:405); and 

 

	 	•	 	“Reconstruction of a-FAS/APO-1 Mediated-Apoptosis In Human Cancer Cells by Adenovirus-Mediated transduction of the Wildtype p53 Gene” patent has not filed yet (MDA Ref. UTSC:417);

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]